{"gene":"VRK1","run_date":"2026-06-11T09:02:06","timeline":{"discoveries":[{"year":1997,"finding":"VRK1 was identified as a novel serine/threonine kinase with 40% amino acid identity to vaccinia virus B1R kinase over 305 residues, establishing it as a member of a new kinase family related to, but distinct from, casein kinase 1.","method":"cDNA cloning, sequence analysis, Northern blotting","journal":"Genomics","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — sequence-based identification with expression data; foundational structural classification but no in vitro kinase activity demonstrated in this paper","pmids":["9344656"],"is_preprint":false},{"year":2000,"finding":"VRK1 phosphorylates p53 specifically at threonine-18 (within the mdm-2 binding site/hydrophobic loop), has strong autophosphorylating activity, and phosphorylates acidic substrates (phosvitin, casein) and basic substrates (histone H2B, myelin basic protein). The C-terminal domain (residues 268–396) contains a nuclear localization signal that targets VRK1 to the nucleus.","method":"In vitro kinase assay with GST-fusion substrates, autophosphorylation assay, GFP-fusion subcellular localization","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct in vitro kinase assay with defined substrate and site, mutagenesis/domain mapping, GFP localization; replicated by subsequent studies","pmids":["10951572"],"is_preprint":false},{"year":2004,"finding":"VRK1 phosphorylates ATF2 at Thr-73 and Ser-62, stabilizing ATF2 protein and increasing its intracellular level. VRK1 colocalizes with ATF2 in the nucleus and forms a stable complex. A kinase-dead VRK1 (K179E) or T73A ATF2 substitution prevents ATF2 accumulation and transcriptional activation. VRK1 and JNK have additive effects on ATF2-dependent transcription at suboptimal doses.","method":"In vitro kinase assay, co-immunoprecipitation, mutagenesis, transcriptional reporter assay, immunofluorescence colocalization","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assay with site mutagenesis, stable complex by Co-IP, functional transcription assay; single lab but multiple orthogonal methods","pmids":["15105425"],"is_preprint":false},{"year":2004,"finding":"VRK1 phosphorylates c-Jun at Ser63 and Ser73 in vitro (the same residues targeted by JNK), stabilizes and accumulates c-Jun protein, activates c-Jun-dependent transcription, and interacts with c-Jun but not with JNK. VRK1 and JNK have additive effects on c-Jun transcriptional activation at suboptimal doses.","method":"In vitro kinase assay, immunoprecipitation, transcriptional reporter assay, western blot for endogenous phospho-c-Jun","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assay with defined phosphosites, Co-IP, functional transcription assay with site mutants; single lab, multiple orthogonal methods","pmids":["15378002"],"is_preprint":false},{"year":2006,"finding":"In C. elegans, VRK-1 (the VRK1 ortholog) phosphorylates BAF-1 and regulates BAF localization. VRK-1 localizes to the nuclear envelope and chromatin in a cell-cycle-dependent manner. Depletion of VRK-1 causes mitotic defects including impaired nuclear envelope formation and BAF delocalization.","method":"RNAi depletion, temperature-sensitive mutant analysis, live imaging, immunofluorescence in C. elegans embryos","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean RNAi/genetic loss-of-function with specific nuclear envelope phenotype, in vivo localization; replicated in later mammalian studies","pmids":["17170708"],"is_preprint":false},{"year":2006,"finding":"VRK1 is an early-response gene: its expression is induced upon serum addition to starved cells (paralleling MYC, FOS, CCND1), and its loss via siRNA causes G1 block in cell division with loss of phosphorylated-Rb and cyclin D1.","method":"Serum stimulation of starved cells, siRNA knockdown, flow cytometry cell cycle analysis, western blot for proliferation markers","journal":"Molecular cancer research : MCR","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA KD with specific cell-cycle phenotype, multiple proliferation markers; single lab","pmids":["16547155"],"is_preprint":false},{"year":2007,"finding":"Most intracellular VRK1 protein is nuclear, but a subpopulation localizes to the cytosol and Golgi apparatus depending on cell type. A T355 phosphomimetic substitution near the nuclear localization signal alters antibody reactivity, suggesting post-translational modification regulates VRK1 subcellular distribution.","method":"Immunofluorescence in cell lines, immunohistochemistry of human biopsies, phosphomimetic mutagenesis","journal":"Archives of biochemistry and biophysics","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, indirect evidence for regulated localization via antibody reactivity differences; no direct functional consequence demonstrated","pmids":["17617371"],"is_preprint":false},{"year":2008,"finding":"VRK1 phosphorylates CREB at Ser133 in vitro and in cells. VRK1 facilitates recruitment of phospho-CREB to the CRE element in the CCND1 promoter to drive cyclin D1 expression. Kinase-dead VRK1 or VRK1 siRNA knockdown fails to activate CREB or CRE-driven transcription. VRK1 is a critical link in the CCND1 expression pathway downstream of Myc overexpression.","method":"In vitro kinase assay, ChIP, siRNA knockdown, luciferase reporter assay, western blot","journal":"Journal of cell science","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assay, ChIP, kinase-dead mutant, functional reporter; single lab with multiple orthogonal methods","pmids":["18713830"],"is_preprint":false},{"year":2008,"finding":"VRK1 downregulation by p53 occurs through the autophagic/lysosomal pathway and requires DRAM (a p53-induced gene in the endosomal-lysosomal compartment). DNA damage (UV, IR, etoposide, doxorubicin) stabilizes p53, induces DRAM, and leads to VRK1 downregulation; this process requires nuclear export of VRK1 (blocked by leptomycin B) and Beclin1, and results in reduced p53 Thr18 phosphorylation.","method":"siRNA knockdown of DRAM, leptomycin B treatment, LC3/p62 western blot, Beclin1 RNAi, overexpression assays","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple siRNA/OE experiments with mechanistic pathway tracing; single lab","pmids":["21386980"],"is_preprint":false},{"year":2008,"finding":"Plk3 interacts with VRK1, forming a stable complex. Plk3 phosphorylates the C-terminal region of VRK1 at Ser342 but VRK1 does not phosphorylate Plk3. Phosphorylation of VRK1 at Ser342 is required for Golgi fragmentation: VRK1 with S342 substitutions is catalytically active but blocks Golgi fragmentation. VRK1 and Plk3 represent consecutive steps in the MEK1-Plk3-VRK1 Golgi fragmentation cascade.","method":"Reciprocal immunoprecipitation, pull-down assay, in vitro kinase assay, siRNA knockdown, immunofluorescence (Golgi marker giantin), dominant-negative approaches","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — reciprocal Co-IP, in vitro kinase assay identifying precise phosphosite, site-mutant epistasis with Golgi fragmentation phenotype; single lab, multiple orthogonal methods","pmids":["19103756"],"is_preprint":false},{"year":2008,"finding":"Ran GTPase interacts with and inhibits VRK1 kinase activity. RanGDP (inactive form, especially RanT24N) strongly inhibits VRK1 autophosphorylation and VRK1-mediated histone H3 phosphorylation; active RanGTP or RanL43E relieves this inhibition. Ran does not interact with RCC1 directly through VRK1, but can form a ternary complex. VRK1 does not phosphorylate Ran or RCC1.","method":"Pulldown of endogenous proteins, reciprocal immunoprecipitation, mass spectrometry, in vitro kinase assay with Ran mutants","journal":"Molecular & cellular proteomics : MCP","confidence":"High","confidence_rationale":"Tier 1 / Moderate — reciprocal Co-IP plus pulldown, in vitro kinase activity assay with defined Ran mutants; single lab with multiple orthogonal methods","pmids":["18617507"],"is_preprint":false},{"year":2008,"finding":"VRK1 is an early-response gene required for cell cycle entry at G0/G1. siRNA-mediated VRK1 loss results in G1 block, loss of phosphorylated-Rb, cyclin D1, and PCNA, and reduced cell proliferation. VRK1 expression is induced by serum and correlates inversely with p27.","method":"siRNA knockdown, serum stimulation, flow cytometry, western blot for cell cycle markers, reporter assay","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA with specific G1 phenotype and multiple proliferation markers; single lab","pmids":["18286197"],"is_preprint":false},{"year":2009,"finding":"VRK1 hypomorphic mice (GT3/GT3, ~15% wild-type VRK1) are viable but infertile. VRK1 is expressed in Sertoli cells and spermatogonia, and its loss results in a progressive defect in spermatogonial proliferation/differentiation, ultimately eliminating mitotic and meiotic cells from adult testis.","method":"Gene-trap mouse genetics, histology, in situ expression analysis","journal":"Biology of reproduction","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — hypomorphic mouse genetic analysis with specific spermatogenesis phenotype; single lab","pmids":["19696012"],"is_preprint":false},{"year":2010,"finding":"In C. elegans, VRK-1 is required for normal germ cell proliferation, and acts in part by negatively regulating CEP-1 (p53) activity. Loss of cep-1 significantly rescues vrk-1 proliferation defects, placing VRK-1 upstream of CEP-1/p53 in germline proliferation control.","method":"Genome-wide RNAi screen, genetic epistasis (double mutant rescue), gene expression profiling","journal":"Developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis by double mutant rescue; single lab","pmids":["20599896"],"is_preprint":false},{"year":2011,"finding":"NMR solution structure of catalytically active human VRK1 (residues 1–361) revealed that the C-terminal tail orients toward the catalytic site and forms interactions critical for structural stability and catalysis. Deletion of the C-terminal tail dramatically reduces autocatalytic activity. ATP binding involves the hinge region, catalytic loop, and DYG motif, with additional contacts from C-terminal tail residues.","method":"NMR solution structure determination, deletion mutant kinase assays, NMR titration with ATP/ATP analogs","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — NMR structure combined with deletion mutagenesis and kinase activity assays; multiple orthogonal methods in single study","pmids":["21543316"],"is_preprint":false},{"year":2011,"finding":"MacroH2A1.2 directly interacts with VRK1 and suppresses VRK1-mediated histone H3 phosphorylation during interphase. MacroH2A1.2 levels are markedly reduced in mitosis, thereby relieving VRK1 inhibition. VRK1-macroH2A1.2 interaction was confirmed by NMR spectroscopy.","method":"Co-immunoprecipitation, NMR spectroscopy (binding characterization), cell cycle synchronization, western blot for H3 phosphorylation","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct binding confirmed by NMR, in-cell functional data with cell cycle correlation; single lab, two orthogonal methods","pmids":["22194607"],"is_preprint":false},{"year":2011,"finding":"The kinase VRK1 is required for normal meiotic progression in female mouse oogenesis. VRK1 reduction (gene-trap hypomorph) causes delayed meiotic progression, lagging chromosomes at the metaphase plate, and failure of oocyte fertilization. These defects are independent of p53 activity.","method":"Gene-trap mouse hypomorph, histology, meiotic chromosome spreads, p53 knockout epistasis","journal":"Mechanisms of development","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic loss-of-function with specific meiotic phenotype and epistasis test; single lab","pmids":["21277975"],"is_preprint":false},{"year":2012,"finding":"VRK1 directly phosphorylates 53BP1 in serum-starved cells in response to ionizing radiation-induced double-strand breaks. VRK1 knockdown causes defective 53BP1 foci formation (reduced number and size) after IR; this effect is p53- and ATM-independent and is rescued by siRNA-resistant VRK1 mutants. VRK1 knockdown also prevents activating phosphorylation of ATM, CHK2, and DNA-PK in response to IR.","method":"In vitro kinase assay, siRNA knockdown, immunofluorescence for 53BP1 foci, western blot for ATM/CHK2/DNA-PK phosphorylation, siRNA-resistant rescue constructs","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assay, siRNA KD with specific foci phenotype, siRNA-resistant rescue, ATM-independent epistasis; single lab, multiple orthogonal methods","pmids":["22621922"],"is_preprint":false},{"year":2012,"finding":"VRK1 phosphorylates hnRNP A1, and this phosphorylation potentiates hnRNP A1 binding to telomeric ssDNA and telomerase RNA in vitro, and enhances telomerase activity. VRK1 deficiency in mouse male germ cells causes telomere shortening with abnormal telomere arrangement and activation of DNA-damage signaling.","method":"In vitro kinase assay, EMSA (ssDNA binding), telomerase activity assay, mouse VRK1 hypomorph analysis","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assay plus functional binding and telomerase assays; single lab, in vivo corroboration from mouse model","pmids":["22740652"],"is_preprint":false},{"year":2014,"finding":"VRK1 depletion in MCF10a and MDA-MB-231 cells causes aberrant nuclear envelope architecture. GFP-BAF FRAP analysis shows elevated immobile fraction at the nuclear envelope in VRK1-depleted cells, indicating prolonged BAF-partner interactions. In VRK1-depleted cells, BAF does not disperse at mitosis onset but remains chromosome-bound throughout mitosis. VRK1 depletion also increases anaphase bridges and multipolar spindles.","method":"siRNA knockdown, FRAP of GFP-BAF, live-cell imaging, immunofluorescence for mitotic phenotypes","journal":"Molecular biology of the cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean KD with live-cell FRAP and imaging demonstrating specific BAF dynamics phenotype; independently consistent with C. elegans findings","pmids":["24430874"],"is_preprint":false},{"year":2014,"finding":"VRK1 forms a basal stable complex with p53 through the p53 DNA-binding domain. UV-induced DNA damage activates VRK1 and triggers phosphorylation of p53 at Thr-18 before p53 accumulates. Frequent DNA-contact p53 mutants (R273H, R248H, R280K) do not disrupt the VRK1-p53 complex.","method":"Co-immunoprecipitation, in vitro kinase assay, UV treatment, western blot for phospho-p53 Thr18","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP demonstrating stable complex, in vitro kinase assay, single lab","pmids":["24492002"],"is_preprint":false},{"year":2015,"finding":"VRK1 is a nucleosomal chromatin kinase that directly and stably interacts with histones H2AX and H3. VRK1 depletion causes loss of H3 and H4 acetylation (required for chromatin relaxation) in basal conditions and after DNA damage, independently of ATM. In response to ionizing radiation, VRK1 phosphorylates histone H2AX at Ser139 (γH2AX); VRK1 depletion prevents γH2AX foci formation, which is rescued by kinase-active but not kinase-dead VRK1.","method":"Chromatin fractionation, Co-immunoprecipitation with histones, siRNA knockdown, ionizing radiation, immunofluorescence for γH2AX foci, kinase-dead rescue","journal":"Epigenetics","confidence":"High","confidence_rationale":"Tier 1 / Moderate — chromatin fractionation, Co-IP with histones, in-cell kinase assay with kinase-dead rescue; single lab, multiple orthogonal methods","pmids":["25923214"],"is_preprint":false},{"year":2015,"finding":"VRK1 directly interacts with and phosphorylates coilin at Ser184. Phosphorylation of coilin by VRK1 occurs during mitosis and regulates coilin stability: VRK1 knockdown or inactivation causes loss of coilin phosphorylation and Cajal body (CB) disassembly, leading to coilin ubiquitination (partly mediated by mdm2) and proteasomal degradation in the cytosol (after nuclear export). Kinase-active but not kinase-dead VRK1 rescues CB formation.","method":"Co-immunoprecipitation, in vitro kinase assay, siRNA knockdown, immunofluorescence, proteasome inhibitor (MG132), nuclear export inhibitor","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assay identifying phosphosite, Co-IP, kinase-dead rescue, proteasome/export inhibitor mechanistic dissection; single lab, multiple orthogonal methods","pmids":["26068304"],"is_preprint":false},{"year":2015,"finding":"VRK1 regulates neuronal migration and neuronal stem cell proliferation. In utero electroporation shRNA knockdown of Vrk1 in mice impairs cortical neuronal migration and affects cell cycle of neuronal progenitors; wild-type human VRK1 rescues both phenotypes. Kinase-dead VRK1 rescues migration but not proliferation, indicating the migration role is partly non-catalytic. VRK1 deficiency reduces amyloid-β precursor protein (APP) levels, and APP overexpression rescues the Vrk1 knockdown neuronal migration phenotype.","method":"In utero electroporation shRNA, cortical migration assay, kinase-dead rescue, western blot for APP, APP overexpression rescue","journal":"The Journal of neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo shRNA with specific neuronal migration phenotype, kinase-dead vs. WT rescue, epistasis through APP; single lab","pmids":["25609612"],"is_preprint":false},{"year":2016,"finding":"VRK1 phosphorylates NBS1 at Ser343, forming a basal preassembled complex with NBS1 in non-damaged cells. VRK1 knockdown causes loss of NBS1 foci after ionizing radiation (also in cell-cycle arrested and ATM−/− cells). NBS1 phosphorylation by VRK1 (induced by doxorubicin or IR) contributes to NBS1 stability: loss of this phosphorylation can be prevented by MG132 proteasome inhibitor or RNF8 knockdown.","method":"Co-immunoprecipitation, in vitro kinase assay (ATM−/− cells), siRNA knockdown, immunofluorescence for NBS1 foci, proteasome inhibitor treatment","journal":"Biochimica et biophysica acta","confidence":"High","confidence_rationale":"Tier 1 / Moderate — basal complex by Co-IP, in vitro kinase assay defining phosphosite, ATM-independent genetic context, proteasome mechanistic link; single lab, multiple orthogonal methods","pmids":["26869104"],"is_preprint":false},{"year":2017,"finding":"VRK1 phosphorylates pregnane X receptor (PXR) at Ser350 in response to low glucose conditions, enabling PXR to scaffold PP2Cα, which dephosphorylates SGK2 at Thr193, releasing SGK2 repression of the PCK1 gluconeogenesis gene. CDK2 inhibits VRK1 activity toward PXR under high glucose conditions, forming a VRK1-CDK2-PXR-PP2Cα-SGK2 pathway regulating gluconeogenesis.","method":"In vitro kinase assay, co-immunoprecipitation, cell-based phosphorylation assays, CDK2 inhibition, fasting mouse liver analysis","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assay with defined phosphosite, co-IP, in vivo fasting mouse corroboration; single lab","pmids":["28911860"],"is_preprint":false},{"year":2018,"finding":"VRK1 and Aurora B (AURKB) form a stable protein complex (minor subpopulation, detected after nocodazole release). Each kinase inhibits the kinase activity of the other, and each inhibits the other's phosphorylation of histone H3 (VRK1 on Thr3, AURKB on Ser10). VRK1 depletion downregulates BIRC5 (survivin) expression and is rescued by kinase-active but not kinase-dead VRK1; loss of the H3-Thr3ph–survivin complex prevents AURKB localization to centromeres.","method":"Co-immunoprecipitation, in vitro kinase assay (cross-inhibition), siRNA knockdown, immunofluorescence, kinase-active vs. kinase-dead rescue","journal":"Cellular and molecular life sciences : CMLS","confidence":"High","confidence_rationale":"Tier 1 / Moderate — Co-IP, in vitro mutual inhibition assay, specific mitotic phenotypes with rescue; single lab, multiple orthogonal methods","pmids":["29340707"],"is_preprint":false},{"year":2020,"finding":"In C. elegans, VRK-1 directly phosphorylates and activates AMPK, promoting longevity. VRK-1 overexpression increases lifespan and inhibition decreases lifespan; vrk-1 is required for longevity conferred by inhibited mitochondrial respiration (which requires AMPK). VRK-1 directly phosphorylates and upregulates AMPK in both C. elegans and human cultured cells.","method":"In vitro kinase assay (direct phosphorylation of AMPK), C. elegans lifespan assays, genetic epistasis with AMPK mutants, overexpression in cultured human cells","journal":"Science advances","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro direct kinase assay, genetic epistasis in C. elegans, conserved in human cells; single lab, multiple orthogonal methods","pmids":["32937443"],"is_preprint":false},{"year":2020,"finding":"VRK1 directly phosphorylates Tip60/KAT5 in the chromatin fraction in response to DNA damage (doxorubicin). VRK1 depletion causes loss of Tip60 phosphorylation in both ATM+/+ and ATM−/− cells; kinase-active but not kinase-dead VRK1 rescues Tip60 phosphorylation. VRK1-mediated Tip60 phosphorylation is necessary for Tip60 acetyltransferase activity toward ATM (activating acetylation) and subsequent ATM autophosphorylation; both are lost by VRK1 depletion.","method":"In vitro kinase assay, Co-immunoprecipitation, siRNA knockdown (ATM+/+ and ATM−/− cells), Tip60 inhibitor (MG149), kinase-active/dead rescue","journal":"Cancers","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assay, ATM-independent genetic context, kinase-dead rescue; single lab, multiple orthogonal methods","pmids":["33076429"],"is_preprint":false},{"year":2021,"finding":"Vaccinia virus B12 pseudokinase directly interacts with VRK1 (as the most enriched B12 interactor by proteomics), and B12 interferes with VRK1's ability to phospho-inactivate BAF. VRK1 is required for rescue of B1-deleted virus; VRK1 overexpression overcomes B12-mediated repression of viral replication. B12 promotes VRK1 colocalization with cellular DNA during mitosis.","method":"Protein interactome (mass spectrometry), VRK1 knockdown and overexpression assays, viral replication assays, immunofluorescence","journal":"Journal of virology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — MS interactome plus functional VRK1 KD/OE in viral context; single lab","pmids":["33177193"],"is_preprint":false},{"year":2022,"finding":"VRK1 interacts with both linker DNA and the nucleosome acidic patch to phosphorylate histone H3T3. Acidic patch binding is mediated by a C-terminal arginine-rich flexible tail. Disease-associated missense and nonsense mutations in this C-terminal acidic patch recognition motif disrupt nucleosome acidic patch binding and cause VRK1 mislocalization during mitosis.","method":"Cryo-electron microscopy, biochemical binding assays (chromatin/nucleosome), cellular localization assays (mitosis), analysis of disease-associated mutants","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1 / Strong — cryo-EM structure with biochemical validation, disease-mutant functional testing, cellular localization consequence; single study with multiple orthogonal methods","pmids":["35390161"],"is_preprint":false},{"year":2022,"finding":"VRK1 and VRK2 are synthetic-lethal paralogs. In VRK2-null/methylated glioblastoma cells, VRK1 knockdown reduces phosphorylation of BAF, causing nuclear lobulation, blebbing, and micronucleation, followed by G2-M arrest and DNA damage. The synthetic-lethal interaction requires VRK1 kinase activity and is rescued by ectopic VRK2 expression.","method":"CRISPR/Cas9 knockdown, VRK2 ectopic expression rescue, phospho-BAF western blot, live-cell imaging (nuclear morphology), flow cytometry (G2-M arrest), xenograft models","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic tools (KD, rescue), specific downstream substrate (BAF), cellular and in vivo phenotypes; replicated in independent study (So et al., 2022)","pmids":["36069976"],"is_preprint":false},{"year":2022,"finding":"The VRK1 chromatin kinase regulates Tip60/KAT5 through sequential phosphorylation events: VRK1 phosphorylates Tip60 at T158 (early, transient), which protects Tip60 from ubiquitin-mediated degradation, promotes its recruitment from nucleoplasm to chromatin, and is necessary for full trans-acetylase activity. DNA-PK subsequently phosphorylates Tip60 at S199, enabling Tip60 autoacetylation; however, full trans-acetylation of H4 and ATM requires both T158 and S199 phosphorylation.","method":"In vitro kinase assay, phosphomimetic and phosphonull mutants, Co-immunoprecipitation, chromatin fractionation, DNA-PK inhibitor treatment","journal":"Biochimica et biophysica acta. Gene regulatory mechanisms","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assay identifying phosphosites, phosphomutant functional assays, chromatin fractionation; single lab, multiple orthogonal methods","pmids":["36280132"],"is_preprint":false},{"year":2022,"finding":"Using in vitro kinase assays, KiPIK screening, RNAi, and CRISPR/Cas9 approaches, VRK1 and its paralog VRK2 could NOT be substantiated as the kinases responsible for histone H3 Thr3 or Ser10 phosphorylation during mitosis; Haspin is the kinase responsible for H3T3ph in mitosis. Loss of VRK1 did slow cell proliferation.","method":"In vitro kinase assays, KiPIK screening, RNA interference, CRISPR/Cas9 knockout","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — multiple rigorous approaches (in vitro assay, KiPIK, RNAi, CRISPR) converging on a negative result; single lab but orthogonal methods","pmids":["35778595"],"is_preprint":false},{"year":2022,"finding":"In zebrafish, Ankle2 deficiency causes microcephaly and spermatogenesis defects through dysregulated BAF phosphorylation. Heterozygous deletion of vrk1 or vrk1 morpholino knockdown rescues the Ankle2-deficient microcephaly and partially rescues spermatogenesis defects, placing VRK1 downstream of ANKLE2 in the BAF phosphorylation pathway regulating neurogenesis.","method":"Zebrafish genetic knockout and morpholino knockdown, genetic epistasis, brain size measurement, cell proliferation assays","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis with specific rescue of neurogenesis phenotype; single lab","pmids":["35940133"],"is_preprint":false},{"year":2023,"finding":"VRK1 kinase activity is inhibited by direct interaction with SIRT2 deacetylase through VRK1's N-terminal kinase domain. VRK1-SIRT2 interaction causes loss of H4K16 acetylation (similar to VRK1 inhibitor VRK-IN-1 or VRK1 depletion). SIRT2 inhibitors increase H4K16ac, cooperating with VRK1 in chromatin accessibility in response to DNA damage.","method":"In vitro interaction/pull-down assay, in vitro kinase assay, Co-immunoprecipitation, immunofluorescence, H4K16ac western blot","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro pull-down and kinase inhibition, Co-IP, functional acetylation readout; single lab","pmids":["36902348"],"is_preprint":false},{"year":2024,"finding":"VRK1 promotes DNA-induced type I interferon production through the cGAS-STING pathway. VRK1 knockdown attenuates induction of type I IFNs and ISGs following HTDNA and Poly(dA:dT) stimulation; VRK-IN-1 (VRK1 inhibitor) similarly suppresses IFN-I induction. VRK1 potentiates the cGAS-STING-IFN-I axis at the level of STING.","method":"siRNA knockdown, pharmacological inhibition (VRK-IN-1), real-time PCR, dual-luciferase reporter assay in human and murine cell lines and primary BMDMs","journal":"Molecular biology reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA KD and pharmacological inhibition with consistent IFN reporter results; single lab, mechanism placement at STING level","pmids":["38536553"],"is_preprint":false},{"year":2025,"finding":"VRK1 directly interacts with and phosphorylates CHD1L at serine 122. VRK1-CHD1L-SNAI1 forms an axis by which VRK1 promotes EMT in hepatocellular carcinoma: VRK1 phosphorylation of CHD1L upregulates SNAI1 expression (identified by RNA-seq as a key downstream target).","method":"Immunoprecipitation combined with mass spectrometry, in vitro kinase assay (phosphosite identification), RNA-seq, VRK1 overexpression/knockdown functional assays","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — Co-IP/MS, in vitro kinase assay with phosphosite, RNA-seq pathway analysis; single lab","pmids":["40234378"],"is_preprint":false}],"current_model":"VRK1 is a nuclear serine/threonine chromatin kinase that phosphorylates multiple substrates—including p53 (Thr18), ATF2 (Thr73/Ser62), c-Jun (Ser63/Ser73), CREB (Ser133), histone H2AX (Ser139), histone H3 (Thr3 in interphase contexts), BAF/BANF1, 53BP1, NBS1 (Ser343), coilin (Ser184), hnRNP A1, Tip60/KAT5 (T158), AMPK, PXR (Ser350), and CHD1L (Ser122)—to regulate cell cycle entry (G0/G1 transition and cyclin D1 expression), nuclear envelope assembly/disassembly via BAF dynamics, Cajal body assembly via coilin stability, chromatin relaxation and histone acetylation (H4K16ac via Tip60 activation), DNA damage responses (γH2AX, NBS1, and 53BP1 foci formation independent of ATM), Golgi fragmentation (as a Plk3-phosphorylated downstream effector at Ser342), and nucleosome engagement through an acidic-patch-binding C-terminal arginine-rich tail; its kinase activity is negatively regulated by RanGDP and macroH2A1.2, and by cross-inhibition with Aurora B, while a paralog synthetic-lethal relationship with VRK2 means VRK2-deficient cancers are uniquely dependent on VRK1."},"narrative":{"mechanistic_narrative":"VRK1 is a nuclear serine/threonine chromatin kinase that couples mitogenic and genotoxic signals to cell cycle entry, chromatin dynamics, nuclear envelope organization, and DNA damage responses [PMID:10951572, PMID:18286197, PMID:25923214]. It was originally cloned as a kinase distantly related to vaccinia virus B1R [PMID:9344656] and shown to autophosphorylate and phosphorylate p53 at Thr18 within the MDM2-binding loop, with a C-terminal nuclear localization signal directing it to the nucleus [PMID:10951572]. As an early-response gene induced by serum, VRK1 drives the G0/G1 transition: its loss blocks cells in G1 with reduced phospho-Rb, cyclin D1, and PCNA [PMID:16547155, PMID:18286197], and it activates cyclin D1 expression by phosphorylating CREB at Ser133 and promoting its recruitment to the CCND1 promoter [PMID:18713830]. VRK1 stabilizes and activates the transcription factors ATF2 and c-Jun through phosphorylation, paralleling JNK targeting [PMID:15105425, PMID:15378002]. In the DNA damage response, VRK1 acts upstream of and independently of ATM, phosphorylating histone H2AX (Ser139/γH2AX), NBS1 (Ser343), and 53BP1 to support damage focus formation, and phosphorylating Tip60/KAT5 at T158 to license its acetyltransferase activity toward histones and ATM [PMID:22621922, PMID:25923214, PMID:26869104, PMID:33076429, PMID:36280132]. Structural work defined a C-terminal tail that folds onto the catalytic site and an arginine-rich tail that engages linker DNA and the nucleosome acidic patch for histone H3T3 phosphorylation; disease-associated mutations in this motif disrupt nucleosome binding and mitotic localization [PMID:21543316, PMID:35390161]. VRK1 regulates nuclear envelope assembly and mitotic chromosome segregation by phosphorylating BAF/BANF1, controlling its dynamic dissociation from chromatin [PMID:17170708, PMID:24430874], and maintains Cajal bodies by phosphorylating coilin at Ser184 to prevent its degradation [PMID:26068304]. Its kinase activity is negatively regulated by RanGDP, macroH2A1.2, SIRT2, and reciprocal cross-inhibition with Aurora B [PMID:18617507, PMID:22194607, PMID:29340707, PMID:36902348]. VRK1 and its paralog VRK2 are synthetic-lethal, rendering VRK2-deficient cancers selectively dependent on VRK1 via BAF phosphorylation [PMID:36069976]. Beyond its core nuclear roles, VRK1 also acts in a Plk3-driven Golgi fragmentation cascade [PMID:19103756], gluconeogenic signaling via PXR [PMID:28911860], AMPK activation and longevity [PMID:32937443], cGAS-STING interferon signaling [PMID:38536553], and EMT through a CHD1L-SNAI1 axis [PMID:40234378].","teleology":[{"year":1997,"claim":"Established VRK1 as a distinct serine/threonine kinase family member, providing the molecular identity needed to study its function.","evidence":"cDNA cloning and sequence analysis against vaccinia B1R kinase","pmids":["9344656"],"confidence":"Medium","gaps":["No in vitro kinase activity or substrate demonstrated","No subcellular localization or cellular role defined"]},{"year":2000,"claim":"Demonstrated VRK1 is a catalytically active nuclear kinase with p53 Thr18 as a defined substrate, opening the link to the p53 stress-response axis.","evidence":"In vitro kinase assays with GST substrates, autophosphorylation, GFP localization and domain mapping","pmids":["10951572"],"confidence":"High","gaps":["Functional consequence of p53 Thr18 phosphorylation not resolved in cells","Physiological substrate repertoire still unknown"]},{"year":2004,"claim":"Extended VRK1 substrate scope to AP-1 transcription factors, showing it stabilizes and activates ATF2 and c-Jun in parallel with the JNK pathway.","evidence":"In vitro kinase assays, Co-IP, site mutagenesis, and transcriptional reporters","pmids":["15105425","15378002"],"confidence":"High","gaps":["In vivo physiological context of these phosphorylations unclear","Relative contribution versus JNK not quantified"]},{"year":2006,"claim":"Defined VRK1 as a serum-induced early-response gene required for the G0/G1 transition, framing it as a proliferation driver.","evidence":"Serum stimulation, siRNA knockdown, flow cytometry, cell-cycle marker western blots","pmids":["16547155","18286197"],"confidence":"Medium","gaps":["Direct kinase substrates mediating G1 arrest not identified here","Single-lab phenotype"]},{"year":2006,"claim":"Established the conserved nuclear-envelope role of VRK1 via BAF phosphorylation using a genetically tractable in vivo model.","evidence":"RNAi and temperature-sensitive mutants with live imaging in C. elegans","pmids":["17170708"],"confidence":"High","gaps":["Direct BAF phosphosite not defined in this study","Mammalian conservation not yet shown at this stage"]},{"year":2008,"claim":"Mechanistically connected VRK1 to cyclin D1 induction through CREB Ser133 phosphorylation and promoter recruitment, downstream of Myc.","evidence":"In vitro kinase assay, ChIP, kinase-dead mutant, luciferase reporter","pmids":["18713830"],"confidence":"High","gaps":["How serum/Myc signal activates VRK1 not resolved","Endogenous CREB occupancy dynamics not fully mapped"]},{"year":2008,"claim":"Identified upstream regulatory inputs: Plk3 phosphorylates VRK1 at Ser342 to drive Golgi fragmentation, and RanGDP inhibits VRK1 activity, revealing signal-dependent control.","evidence":"Reciprocal Co-IP, in vitro kinase assays, site-mutant epistasis, pulldown with Ran mutants","pmids":["19103756","18617507"],"confidence":"High","gaps":["Physiological trigger linking Ran nucleotide state to VRK1 in vivo unclear","Golgi role mechanism downstream of Ser342 incomplete"]},{"year":2008,"claim":"Showed a feedback loop in which p53 downregulates VRK1 via DRAM-dependent autophagy, defining reciprocal regulation between VRK1 and p53.","evidence":"DRAM/Beclin1 siRNA, leptomycin B, autophagy marker western blots","pmids":["21386980"],"confidence":"Medium","gaps":["Direct mechanism of VRK1 autophagic targeting not defined","Single-lab pathway tracing"]},{"year":2009,"claim":"Demonstrated physiological requirement for VRK1 in proliferating germline tissue through a hypomorphic mouse with spermatogenesis failure.","evidence":"Gene-trap mouse genetics, histology, expression analysis","pmids":["19696012"],"confidence":"Medium","gaps":["Molecular substrate underlying spermatogonial defect not identified here","Hypomorph rather than null"]},{"year":2010,"claim":"Placed VRK1 genetically upstream of p53 in controlling germ cell proliferation, reinforcing a conserved VRK1–p53 antagonism.","evidence":"Genome-wide RNAi and double-mutant epistasis in C. elegans","pmids":["20599896"],"confidence":"Medium","gaps":["Direct biochemical link to CEP-1/p53 not established","Mechanism of negative regulation unclear"]},{"year":2011,"claim":"Provided the structural basis of VRK1 catalysis, showing the C-terminal tail is integral to activity, and identified macroH2A1.2 as a cell-cycle-dependent inhibitor.","evidence":"NMR solution structure, deletion-mutant kinase assays, NMR binding of macroH2A1.2","pmids":["21543316","22194607"],"confidence":"High","gaps":["Full-length structure including arginine-rich tail not resolved here","How macroH2A1.2 occludes catalysis structurally unknown"]},{"year":2011,"claim":"Extended VRK1's developmental requirement to female meiosis, with chromosome segregation defects independent of p53.","evidence":"Gene-trap hypomorph, meiotic chromosome spreads, p53-knockout epistasis","pmids":["21277975"],"confidence":"Medium","gaps":["Substrate driving meiotic defect not identified","Hypomorphic rather than null"]},{"year":2012,"claim":"Established VRK1 as an ATM-independent apical DNA damage response kinase that phosphorylates 53BP1 and supports damage signaling and telomere maintenance via hnRNP A1.","evidence":"In vitro kinase assays, siRNA with focus quantification, siRNA-resistant rescue, EMSA and telomerase assays","pmids":["22621922","22740652"],"confidence":"High","gaps":["How VRK1 is activated by double-strand breaks unresolved","Direct 53BP1 phosphosite not defined"]},{"year":2014,"claim":"Quantified VRK1's control of BAF mobility in mammalian cells, linking BAF phosphorylation to nuclear envelope architecture and faithful mitosis.","evidence":"siRNA knockdown, GFP-BAF FRAP, live-cell imaging, mitotic phenotype scoring","pmids":["24430874"],"confidence":"High","gaps":["Direct BAF phosphosite in mammalian cells not mapped here","Spatial coordination of BAF phosphorylation cycle incomplete"]},{"year":2014,"claim":"Showed VRK1 forms a basal complex with p53 via its DNA-binding domain and rapidly phosphorylates Thr18 upon UV damage before p53 accumulation.","evidence":"Co-IP, in vitro kinase assay, UV treatment, phospho-p53 western blot","pmids":["24492002"],"confidence":"Medium","gaps":["Stoichiometry and dynamics of the preassembled complex unclear","Reciprocal validation limited"]},{"year":2015,"claim":"Defined VRK1 as a nucleosomal chromatin kinase required for histone acetylation and γH2AX formation, and as a regulator of Cajal body integrity and neuronal development.","evidence":"Chromatin fractionation, histone Co-IP, kinase-dead rescue, coilin phosphosite mapping, in utero electroporation shRNA","pmids":["25923214","26068304","25609612"],"confidence":"High","gaps":["Mechanism linking VRK1 to H3/H4 acetylation machinery only partly defined","Non-catalytic migration function mechanism unknown"]},{"year":2016,"claim":"Identified NBS1 Ser343 as a VRK1 substrate within a preassembled complex, contributing to NBS1 stability and ATM-independent damage focus formation.","evidence":"Co-IP, in vitro kinase assay in ATM-/- cells, focus imaging, proteasome inhibition, RNF8 knockdown","pmids":["26869104"],"confidence":"High","gaps":["Integration with canonical MRN/ATM signaling not fully resolved","Single-lab"]},{"year":2017,"claim":"Expanded VRK1 into metabolic signaling, phosphorylating PXR Ser350 to control a gluconeogenic cascade gated by CDK2 and glucose status.","evidence":"In vitro kinase assay, Co-IP, glucose-dependent assays, fasting mouse liver","pmids":["28911860"],"confidence":"Medium","gaps":["Tissue-specificity and physiological magnitude unclear","Single-lab pathway"]},{"year":2018,"claim":"Revealed mutual cross-inhibition between VRK1 and Aurora B over histone H3 phosphorylation, coupling VRK1 to mitotic survivin/centromere function.","evidence":"Co-IP, in vitro cross-inhibition kinase assays, kinase-active vs dead rescue, mitotic imaging","pmids":["29340707"],"confidence":"High","gaps":["Spatiotemporal regulation of the antagonism in mitosis unclear","Structural basis of cross-inhibition unknown"]},{"year":2020,"claim":"Mechanistically dissected VRK1 control of Tip60/KAT5, showing T158 phosphorylation licenses Tip60 acetyltransferase activity toward ATM and histones in a sequential code with DNA-PK.","evidence":"In vitro kinase assays, ATM-/- context, phosphomutants, chromatin fractionation, DNA-PK inhibition","pmids":["33076429","36280132"],"confidence":"High","gaps":["Ordering of VRK1 versus DNA-PK inputs across damage types incomplete","Single-lab"]},{"year":2020,"claim":"Demonstrated a conserved VRK1 role in activating AMPK to promote longevity, broadening its substrate range beyond chromatin.","evidence":"In vitro kinase assay, C. elegans lifespan and epistasis, human cell corroboration","pmids":["32937443"],"confidence":"High","gaps":["AMPK phosphosite and mammalian physiological role not defined","Link to nuclear functions unclear"]},{"year":2021,"claim":"Showed vaccinia B12 pseudokinase targets VRK1 to block its inactivation of BAF, defining a host-pathogen control point at the VRK1–BAF interface.","evidence":"Proteomic interactome, VRK1 KD/OE, viral replication assays, imaging","pmids":["33177193"],"confidence":"Medium","gaps":["Direct biochemical mechanism of B12 inhibition unresolved","Single-lab"]},{"year":2022,"claim":"Provided the structural mechanism of nucleosome engagement, showing an arginine-rich C-terminal tail binds the acidic patch and linker DNA, with disease mutations disrupting this and mitotic localization.","evidence":"Cryo-EM, nucleosome binding assays, disease-mutant localization tests","pmids":["35390161"],"confidence":"High","gaps":["Functional consequence of disrupted acidic-patch binding on substrate phosphorylation in vivo incomplete","Disease genotype-phenotype not mapped here"]},{"year":2022,"claim":"Established VRK1–VRK2 synthetic lethality through BAF phosphorylation, defining a therapeutic dependency in VRK2-deficient cancers.","evidence":"CRISPR knockdown, VRK2 rescue, phospho-BAF blots, imaging, flow cytometry, xenografts","pmids":["36069976"],"confidence":"High","gaps":["Determinants of selectivity beyond BAF unclear","Resistance mechanisms not addressed"]},{"year":2022,"claim":"Challenged the assignment of mitotic H3T3/S10 phosphorylation to VRK1, attributing mitotic H3T3ph to Haspin and constraining VRK1's interphase chromatin role.","evidence":"In vitro kinase assays, KiPIK screening, RNAi, CRISPR knockout","pmids":["35778595"],"confidence":"Medium","gaps":["Reconciliation with VRK1 H3T3 activity reported elsewhere unresolved","Context-dependence of H3 phosphorylation not settled"]},{"year":2023,"claim":"Identified SIRT2 as a direct inhibitor of VRK1 controlling H4K16 acetylation and chromatin accessibility during the damage response.","evidence":"In vitro pull-down and kinase inhibition, Co-IP, H4K16ac western blot, imaging","pmids":["36902348"],"confidence":"Medium","gaps":["Whether inhibition is allosteric or steric unclear","Single-lab"]},{"year":2024,"claim":"Linked VRK1 to innate immune signaling, showing it potentiates cGAS-STING-dependent type I interferon production at the STING level.","evidence":"siRNA, VRK-IN-1 inhibition, qPCR and reporter assays in human/murine cells and BMDMs","pmids":["38536553"],"confidence":"Medium","gaps":["Direct STING-pathway substrate not identified","Mechanism of STING-level potentiation unresolved"]},{"year":2025,"claim":"Defined a VRK1–CHD1L–SNAI1 axis driving EMT in hepatocellular carcinoma, extending VRK1's oncogenic reach.","evidence":"Co-IP/MS, in vitro kinase assay with phosphosite, RNA-seq, KD/OE functional assays","pmids":["40234378"],"confidence":"Medium","gaps":["In vivo tumor relevance not fully established","Single-lab"]},{"year":null,"claim":"How VRK1 kinase activity is switched on by distinct mitogenic versus genotoxic upstream signals, and how its many substrate engagements are spatially and temporally prioritized, remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model of VRK1 activation upstream of DNA damage","Substrate selection logic across cell-cycle phases undefined","Context dependence of H3T3 phosphorylation unsettled"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[1,2,3,7,17,21,22,24,28,30,32,37]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,1,14]},{"term_id":"GO:0042393","term_label":"histone binding","supporting_discovery_ids":[21,30]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[30]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[26,28,32,35]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[1,6,21]},{"term_id":"GO:0000228","term_label":"nuclear chromosome","supporting_discovery_ids":[4,21,30]},{"term_id":"GO:0005635","term_label":"nuclear envelope","supporting_discovery_ids":[4,19]},{"term_id":"GO:0005794","term_label":"Golgi apparatus","supporting_discovery_ids":[6,9]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[6]}],"pathway":[{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[5,7,11,19,26]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[17,21,24,28,32]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[21,28,30,32,35]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[2,3,7,37]},{"term_id":"R-HSA-1852241","term_label":"Organelle biogenesis and maintenance","supporting_discovery_ids":[4,19,22]}],"complexes":[],"partners":["TP53","ATF2","JUN","BANF1","NBS1","KAT5","AURKB","PLK3"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q99986","full_name":"Serine/threonine-protein kinase VRK1","aliases":["Vaccinia-related kinase 1"],"length_aa":396,"mass_kda":45.5,"function":"Serine/threonine kinase involved in the regulation of key cellular processes including the cell cycle, nuclear condensation, transcription regulation, and DNA damage response (PubMed:14645249, PubMed:18617507, PubMed:19103756, PubMed:33076429). Controls chromatin organization and remodeling by mediating phosphorylation of histone H3 on 'Thr-4' and histone H2AX (H2aXT4ph) (PubMed:31527692, PubMed:37179361). It also phosphorylates KAT5 in response to DNA damage, promoting KAT5 association with chromatin and histone acetyltransferase activity (PubMed:33076429). Is involved in the regulation of cell cycle progression of neural progenitors, and is required for proper cortical neuronal migration (By similarity). Is involved in neurite elongation and branching in motor neurons, and has an essential role in Cajal bodies assembly, acting through COIL phosphorylation and the control of coilin degradation (PubMed:21920476, PubMed:31090908, PubMed:31527692). Involved in Golgi disassembly during the cell cycle: following phosphorylation by PLK3 during mitosis, it is required to induce Golgi fragmentation (PubMed:19103756). Phosphorylates BANF1: disrupts its ability to bind DNA, reduces its binding to LEM domain-containing proteins and causes its relocalization from the nucleus to the cytoplasm (PubMed:16495336). Phosphorylates TP53BP1 and p53/TP53 on 'Thr-18', preventing the interaction between p53/TP53 and MDM2 (PubMed:10951572, PubMed:31527692). Phosphorylates ATF2 which activates its transcriptional activity (PubMed:15105425). Phosphorylates JUN (PubMed:31527692)","subcellular_location":"Nucleus; Cytoplasm; Nucleus, Cajal body","url":"https://www.uniprot.org/uniprotkb/Q99986/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/VRK1","classification":"Not Classified","n_dependent_lines":607,"n_total_lines":1208,"dependency_fraction":0.5024834437086093},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"CLNS1A","stoichiometry":0.2},{"gene":"MYO9B","stoichiometry":0.2},{"gene":"SMARCA1","stoichiometry":0.2},{"gene":"LAMTOR2","stoichiometry":0.2},{"gene":"KIF22","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/VRK1","total_profiled":1310},"omim":[{"mim_id":"620542","title":"NEURONOPATHY, DISTAL HEREDITARY MOTOR, AUTOSOMAL RECESSIVE 10; HMNR10","url":"https://www.omim.org/entry/620542"},{"mim_id":"619771","title":"VRK SERINE/THREONINE KINASE 3; VRK3","url":"https://www.omim.org/entry/619771"},{"mim_id":"616062","title":"ANKYRIN REPEAT- AND LEM DOMAIN-CONTAINING PROTEIN 2; ANKLE2","url":"https://www.omim.org/entry/616062"},{"mim_id":"607596","title":"PONTOCEREBELLAR HYPOPLASIA, TYPE 1A; PCH1A","url":"https://www.omim.org/entry/607596"},{"mim_id":"604320","title":"NEURONOPATHY, DISTAL HEREDITARY MOTOR, AUTOSOMAL RECESSIVE 1; HMNR1","url":"https://www.omim.org/entry/604320"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"bone marrow","ntpm":48.2}],"url":"https://www.proteinatlas.org/search/VRK1"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"Q99986","domains":[{"cath_id":"3.30.200.20","chopping":"21-133","consensus_level":"medium","plddt":93.7996,"start":21,"end":133},{"cath_id":"1.10.510.10","chopping":"135-344","consensus_level":"medium","plddt":96.4967,"start":135,"end":344}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q99986","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q99986-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q99986-F1-predicted_aligned_error_v6.png","plddt_mean":85.0},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=VRK1","jax_strain_url":"https://www.jax.org/strain/search?query=VRK1"},"sequence":{"accession":"Q99986","fasta_url":"https://rest.uniprot.org/uniprotkb/Q99986.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q99986/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q99986"}},"corpus_meta":[{"pmid":"17170708","id":"PMC_17170708","title":"Caenorhabditis elegans BAF-1 and its kinase VRK-1 participate directly in post-mitotic nuclear envelope assembly.","date":"2006","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/17170708","citation_count":183,"is_preprint":false},{"pmid":"19646678","id":"PMC_19646678","title":"Spinal muscular atrophy with pontocerebellar hypoplasia is caused by a mutation in the VRK1 gene.","date":"2009","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19646678","citation_count":130,"is_preprint":false},{"pmid":"9344656","id":"PMC_9344656","title":"Identification of two novel human putative serine/threonine kinases, VRK1 and VRK2, with structural similarity to vaccinia virus B1R kinase.","date":"1997","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/9344656","citation_count":122,"is_preprint":false},{"pmid":"10951572","id":"PMC_10951572","title":"The human vaccinia-related kinase 1 (VRK1) phosphorylates threonine-18 within the mdm-2 binding site of the p53 tumour suppressor protein.","date":"2000","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/10951572","citation_count":118,"is_preprint":false},{"pmid":"15105425","id":"PMC_15105425","title":"Human vaccinia-related kinase 1 (VRK1) activates the ATF2 transcriptional activity by novel phosphorylation on Thr-73 and Ser-62 and cooperates with JNK.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15105425","citation_count":103,"is_preprint":false},{"pmid":"15378002","id":"PMC_15378002","title":"c-Jun phosphorylation by the human vaccinia-related kinase 1 (VRK1) and its cooperation with the N-terminal kinase of c-Jun (JNK).","date":"2004","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/15378002","citation_count":94,"is_preprint":false},{"pmid":"18286197","id":"PMC_18286197","title":"Human VRK1 is an early response gene and its loss causes a block in cell cycle progression.","date":"2008","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/18286197","citation_count":90,"is_preprint":false},{"pmid":"18713830","id":"PMC_18713830","title":"VRK1 phosphorylates CREB and mediates CCND1 expression.","date":"2008","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/18713830","citation_count":84,"is_preprint":false},{"pmid":"24430874","id":"PMC_24430874","title":"Depletion of the protein kinase VRK1 disrupts nuclear envelope morphology and leads to BAF retention on mitotic chromosomes.","date":"2014","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/24430874","citation_count":78,"is_preprint":false},{"pmid":"16547155","id":"PMC_16547155","title":"VRK1 signaling pathway in the context of the proliferation phenotype in head and neck squamous cell carcinoma.","date":"2006","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/16547155","citation_count":74,"is_preprint":false},{"pmid":"21514377","id":"PMC_21514377","title":"Roles of VRK1 as a new player in the control of biological processes required for cell division.","date":"2011","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/21514377","citation_count":71,"is_preprint":false},{"pmid":"24126608","id":"PMC_24126608","title":"Mutations in VRK1 associated with complex motor and sensory axonal neuropathy plus microcephaly.","date":"2013","source":"JAMA neurology","url":"https://pubmed.ncbi.nlm.nih.gov/24126608","citation_count":61,"is_preprint":false},{"pmid":"29221160","id":"PMC_29221160","title":"Circular RNA profile indicates circular RNA VRK1 is negatively related with breast cancer stem cells.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29221160","citation_count":58,"is_preprint":false},{"pmid":"25923214","id":"PMC_25923214","title":"VRK1 chromatin kinase phosphorylates H2AX and is required for foci formation induced by DNA damage.","date":"2015","source":"Epigenetics","url":"https://pubmed.ncbi.nlm.nih.gov/25923214","citation_count":57,"is_preprint":false},{"pmid":"19103756","id":"PMC_19103756","title":"Plk3 interacts with and specifically phosphorylates VRK1 in Ser342, a downstream target in a pathway that induces Golgi fragmentation.","date":"2008","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/19103756","citation_count":52,"is_preprint":false},{"pmid":"22621922","id":"PMC_22621922","title":"Vaccinia-related kinase 1 (VRK1) is an upstream nucleosomal kinase required for the assembly of 53BP1 foci in response to ionizing radiation-induced DNA damage.","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22621922","citation_count":51,"is_preprint":false},{"pmid":"21386980","id":"PMC_21386980","title":"Downregulation of VRK1 by p53 in response to DNA damage is mediated by the autophagic pathway.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21386980","citation_count":50,"is_preprint":false},{"pmid":"31629252","id":"PMC_31629252","title":"Ginsenoside Rg3 regulates DNA damage in non-small cell lung cancer cells by activating VRK1/P53BP1 pathway.","date":"2019","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/31629252","citation_count":49,"is_preprint":false},{"pmid":"33516791","id":"PMC_33516791","title":"The human VRK1 chromatin kinase in cancer biology.","date":"2021","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/33516791","citation_count":46,"is_preprint":false},{"pmid":"19696012","id":"PMC_19696012","title":"Mice deficient in the serine/threonine protein kinase VRK1 are infertile due to a progressive loss of spermatogonia.","date":"2009","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/19696012","citation_count":44,"is_preprint":false},{"pmid":"17617371","id":"PMC_17617371","title":"Identification of a dominant epitope in human vaccinia-related kinase 1 (VRK1) and detection of different intracellular subpopulations.","date":"2007","source":"Archives of biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/17617371","citation_count":44,"is_preprint":false},{"pmid":"29679095","id":"PMC_29679095","title":"Implication of the VRK1 chromatin kinase in the signaling responses to DNA damage: a therapeutic target?","date":"2018","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/29679095","citation_count":42,"is_preprint":false},{"pmid":"29340707","id":"PMC_29340707","title":"VRK1 and AURKB form a complex that cross inhibit their kinase activity and the phosphorylation of histone H3 in the progression of mitosis.","date":"2018","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/29340707","citation_count":41,"is_preprint":false},{"pmid":"18617507","id":"PMC_18617507","title":"Proteomics identification of nuclear Ran GTPase as an inhibitor of human VRK1 and VRK2 (vaccinia-related kinase) activities.","date":"2008","source":"Molecular & cellular proteomics : MCP","url":"https://pubmed.ncbi.nlm.nih.gov/18617507","citation_count":41,"is_preprint":false},{"pmid":"24492002","id":"PMC_24492002","title":"VRK1 interacts with p53 forming a basal complex that is activated by UV-induced DNA damage.","date":"2014","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/24492002","citation_count":39,"is_preprint":false},{"pmid":"17689819","id":"PMC_17689819","title":"Alteration of the VRK1-p53 autoregulatory loop in human lung carcinomas.","date":"2007","source":"Lung cancer (Amsterdam, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/17689819","citation_count":38,"is_preprint":false},{"pmid":"24731990","id":"PMC_24731990","title":"Vaccinia-related kinase 1 (VRK1) confers resistance to DNA-damaging agents in human breast cancer by affecting DNA damage response.","date":"2014","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/24731990","citation_count":38,"is_preprint":false},{"pmid":"21829721","id":"PMC_21829721","title":"Differential inhibitor sensitivity between human kinases VRK1 and VRK2.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21829721","citation_count":38,"is_preprint":false},{"pmid":"22194607","id":"PMC_22194607","title":"Macro histone H2A1.2 (macroH2A1) protein suppresses mitotic kinase VRK1 during interphase.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22194607","citation_count":36,"is_preprint":false},{"pmid":"21543316","id":"PMC_21543316","title":"NMR solution structure of human vaccinia-related kinase 1 (VRK1) reveals the C-terminal tail essential for its structural stability and autocatalytic activity.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21543316","citation_count":36,"is_preprint":false},{"pmid":"26068304","id":"PMC_26068304","title":"VRK1 regulates Cajal body dynamics and protects coilin from proteasomal degradation in cell cycle.","date":"2015","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26068304","citation_count":34,"is_preprint":false},{"pmid":"22740652","id":"PMC_22740652","title":"HnRNP A1 phosphorylated by VRK1 stimulates telomerase and its binding to telomeric DNA sequence.","date":"2012","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/22740652","citation_count":34,"is_preprint":false},{"pmid":"23732708","id":"PMC_23732708","title":"Molecular genetic analysis of VRK1 in mammary epithelial cells: depletion slows proliferation in vitro and tumor growth and metastasis in vivo.","date":"2013","source":"Oncogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/23732708","citation_count":34,"is_preprint":false},{"pmid":"25609612","id":"PMC_25609612","title":"The spinal muscular atrophy with pontocerebellar hypoplasia gene VRK1 regulates neuronal migration through an amyloid-β precursor protein-dependent mechanism.","date":"2015","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/25609612","citation_count":33,"is_preprint":false},{"pmid":"27281532","id":"PMC_27281532","title":"Novel motor phenotypes in patients with VRK1 mutations without pontocerebellar hypoplasia.","date":"2016","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/27281532","citation_count":33,"is_preprint":false},{"pmid":"36069976","id":"PMC_36069976","title":"VRK1 Is a Synthetic-Lethal Target in VRK2-Deficient Glioblastoma.","date":"2022","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/36069976","citation_count":32,"is_preprint":false},{"pmid":"31101118","id":"PMC_31101118","title":"Olaparib and ionizing radiation trigger a cooperative DNA-damage repair response that is impaired by depletion of the VRK1 chromatin kinase.","date":"2019","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/31101118","citation_count":31,"is_preprint":false},{"pmid":"26869104","id":"PMC_26869104","title":"VRK1 phosphorylates and protects NBS1 from ubiquitination and proteasomal degradation in response to DNA damage.","date":"2016","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/26869104","citation_count":30,"is_preprint":false},{"pmid":"26583493","id":"PMC_26583493","title":"Expanding Phenotype of VRK1 Mutations in Motor Neuron Disease.","date":"2015","source":"Journal of clinical neuromuscular disease","url":"https://pubmed.ncbi.nlm.nih.gov/26583493","citation_count":30,"is_preprint":false},{"pmid":"21277975","id":"PMC_21277975","title":"The kinase VRK1 is required for normal meiotic progression in mammalian oogenesis.","date":"2011","source":"Mechanisms of development","url":"https://pubmed.ncbi.nlm.nih.gov/21277975","citation_count":29,"is_preprint":false},{"pmid":"28298069","id":"PMC_28298069","title":"Expression of VRK1 and the downstream gene BANF1 in esophageal cancer.","date":"2017","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/28298069","citation_count":28,"is_preprint":false},{"pmid":"34071140","id":"PMC_34071140","title":"HNRNP A1 Promotes Lung Cancer Cell Proliferation by Modulating VRK1 Translation.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34071140","citation_count":28,"is_preprint":false},{"pmid":"33076429","id":"PMC_33076429","title":"VRK1 Phosphorylates Tip60/KAT5 and Is Required for H4K16 Acetylation in Response to DNA Damage.","date":"2020","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/33076429","citation_count":27,"is_preprint":false},{"pmid":"31527692","id":"PMC_31527692","title":"VRK1 functional insufficiency due to alterations in protein stability or kinase activity of human VRK1 pathogenic variants implicated in neuromotor syndromes.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31527692","citation_count":27,"is_preprint":false},{"pmid":"32937443","id":"PMC_32937443","title":"VRK-1 extends life span by activation of AMPK via phosphorylation.","date":"2020","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/32937443","citation_count":27,"is_preprint":false},{"pmid":"33738906","id":"PMC_33738906","title":"Circular RNA VRK1 facilitates pre-eclampsia progression via sponging miR-221-3P to regulate PTEN/Akt.","date":"2021","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33738906","citation_count":26,"is_preprint":false},{"pmid":"29029460","id":"PMC_29029460","title":"VRK1 promotes cisplatin resistance by up-regulating c-MYC via c-Jun activation and serves as a therapeutic target in esophageal squamous cell carcinoma.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29029460","citation_count":25,"is_preprint":false},{"pmid":"28911860","id":"PMC_28911860","title":"Glucose elicits serine/threonine kinase VRK1 to phosphorylate nuclear pregnane X receptor as a novel hepatic gluconeogenic signal.","date":"2017","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/28911860","citation_count":24,"is_preprint":false},{"pmid":"30180179","id":"PMC_30180179","title":"Overexpression of the VRK1 kinase, which is associated with breast cancer, induces a mesenchymal to epithelial transition in mammary epithelial cells.","date":"2018","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/30180179","citation_count":23,"is_preprint":false},{"pmid":"30617279","id":"PMC_30617279","title":"A novel mutation in VRK1 associated with distal spinal muscular atrophy.","date":"2019","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30617279","citation_count":23,"is_preprint":false},{"pmid":"18612383","id":"PMC_18612383","title":"The C/H3 domain of p300 is required to protect VRK1 and VRK2 from their downregulation induced by p53.","date":"2008","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/18612383","citation_count":23,"is_preprint":false},{"pmid":"20599896","id":"PMC_20599896","title":"Genome-wide analysis of germ cell proliferation in C.elegans identifies VRK-1 as a key regulator of CEP-1/p53.","date":"2010","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/20599896","citation_count":23,"is_preprint":false},{"pmid":"36040810","id":"PMC_36040810","title":"VRK1 as a synthetic lethal target in VRK2 promoter-methylated cancers of the nervous system.","date":"2022","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/36040810","citation_count":22,"is_preprint":false},{"pmid":"35390161","id":"PMC_35390161","title":"Multivalent DNA and nucleosome acidic patch interactions specify VRK1 mitotic localization and activity.","date":"2022","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/35390161","citation_count":22,"is_preprint":false},{"pmid":"31090908","id":"PMC_31090908","title":"Loss of Cajal bodies in motor neurons from patients with novel mutations in VRK1.","date":"2019","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/31090908","citation_count":22,"is_preprint":false},{"pmid":"26706601","id":"PMC_26706601","title":"High VRK1 expression contributes to cell proliferation and survival in hepatocellular carcinoma.","date":"2015","source":"Pathology, research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/26706601","citation_count":20,"is_preprint":false},{"pmid":"30847374","id":"PMC_30847374","title":"A novel VRK1 mutation associated with recessive distal hereditary motor neuropathy.","date":"2018","source":"Annals of clinical and translational neurology","url":"https://pubmed.ncbi.nlm.nih.gov/30847374","citation_count":19,"is_preprint":false},{"pmid":"33233777","id":"PMC_33233777","title":"Identification of VRK1 as a New Neuroblastoma Tumor Progression Marker Regulating Cell Proliferation.","date":"2020","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/33233777","citation_count":18,"is_preprint":false},{"pmid":"31560180","id":"PMC_31560180","title":"Motor neuron diseases caused by a novel VRK1 variant - A genotype/phenotype study.","date":"2019","source":"Annals of clinical and translational neurology","url":"https://pubmed.ncbi.nlm.nih.gov/31560180","citation_count":18,"is_preprint":false},{"pmid":"34195200","id":"PMC_34195200","title":"VRK1 Depletion Facilitates the Synthetic Lethality of Temozolomide and Olaparib in Glioblastoma Cells.","date":"2021","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/34195200","citation_count":16,"is_preprint":false},{"pmid":"19679119","id":"PMC_19679119","title":"Protein kinase VRK-1 regulates cell invasion and EGL-17/FGF signaling in Caenorhabditis elegans.","date":"2009","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/19679119","citation_count":15,"is_preprint":false},{"pmid":"32724356","id":"PMC_32724356","title":"Downregulation of VRK1 reduces the expression of BANF1 and suppresses the proliferative and migratory activity of esophageal cancer cells.","date":"2020","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/32724356","citation_count":15,"is_preprint":false},{"pmid":"31178479","id":"PMC_31178479","title":"Novel VRK1 Mutations in a Patient with Childhood-onset Motor Neuron Disease.","date":"2019","source":"Internal medicine (Tokyo, Japan)","url":"https://pubmed.ncbi.nlm.nih.gov/31178479","citation_count":15,"is_preprint":false},{"pmid":"30050127","id":"PMC_30050127","title":"Vrk1 partial Knockdown in Mice Results in Reduced Brain Weight and Mild Motor Dysfunction, and Indicates Neuronal VRK1 Target Pathways.","date":"2018","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/30050127","citation_count":14,"is_preprint":false},{"pmid":"32365420","id":"PMC_32365420","title":"VRK1 (Y213H) homozygous mutant impairs Cajal bodies in a hereditary case of distal motor neuropathy.","date":"2020","source":"Annals of clinical and translational neurology","url":"https://pubmed.ncbi.nlm.nih.gov/32365420","citation_count":14,"is_preprint":false},{"pmid":"31837156","id":"PMC_31837156","title":"Identification of a homozygous VRK1 mutation in two patients with adult-onset distal hereditary motor neuropathy.","date":"2020","source":"Muscle & nerve","url":"https://pubmed.ncbi.nlm.nih.gov/31837156","citation_count":14,"is_preprint":false},{"pmid":"28927264","id":"PMC_28927264","title":"Comparative Interactomes of VRK1 and VRK3 with Their Distinct Roles in the Cell Cycle of Liver Cancer.","date":"2017","source":"Molecules and cells","url":"https://pubmed.ncbi.nlm.nih.gov/28927264","citation_count":13,"is_preprint":false},{"pmid":"35940133","id":"PMC_35940133","title":"Ankle2 deficiency-associated microcephaly and spermatogenesis defects in zebrafish are alleviated by heterozygous deletion of vrk1.","date":"2022","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/35940133","citation_count":13,"is_preprint":false},{"pmid":"27334688","id":"PMC_27334688","title":"Oncogenic Sox2 regulates and cooperates with VRK1 in cell cycle progression and differentiation.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27334688","citation_count":12,"is_preprint":false},{"pmid":"37179361","id":"PMC_37179361","title":"The pattern of histone H3 epigenetic posttranslational modifications is regulated by the VRK1 chromatin kinase.","date":"2023","source":"Epigenetics & chromatin","url":"https://pubmed.ncbi.nlm.nih.gov/37179361","citation_count":12,"is_preprint":false},{"pmid":"36280132","id":"PMC_36280132","title":"The VRK1 chromatin kinase regulates the acetyltransferase activity of Tip60/KAT5 by sequential phosphorylations in response to DNA damage.","date":"2022","source":"Biochimica et biophysica acta. Gene regulatory mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/36280132","citation_count":12,"is_preprint":false},{"pmid":"36902348","id":"PMC_36902348","title":"VRK1 Kinase Activity Modulating Histone H4K16 Acetylation Inhibited by SIRT2 and VRK-IN-1.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36902348","citation_count":11,"is_preprint":false},{"pmid":"37257665","id":"PMC_37257665","title":"VRK1 variants at the cross road of Cajal body neuropathogenic mechanisms in distal neuropathies and motor neuron diseases.","date":"2023","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/37257665","citation_count":11,"is_preprint":false},{"pmid":"32242460","id":"PMC_32242460","title":"VRK1 variants in two Portuguese unrelated patients with childhood-onset motor neuron disease.","date":"2020","source":"Amyotrophic lateral sclerosis & frontotemporal degeneration","url":"https://pubmed.ncbi.nlm.nih.gov/32242460","citation_count":11,"is_preprint":false},{"pmid":"34169149","id":"PMC_34169149","title":"Adult-Onset Spinal Muscular Atrophy due to Mutations in the VRK1 Gene.","date":"2021","source":"Neurology. Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34169149","citation_count":11,"is_preprint":false},{"pmid":"35778595","id":"PMC_35778595","title":"Dissecting the roles of Haspin and VRK1 in histone H3 phosphorylation during mitosis.","date":"2022","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/35778595","citation_count":10,"is_preprint":false},{"pmid":"34504951","id":"PMC_34504951","title":"Dysfunctional Homozygous VRK1-D263G Variant Impairs the Assembly of Cajal Bodies and DNA Damage Response in Hereditary Spastic Paraplegia.","date":"2021","source":"Neurology. Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34504951","citation_count":9,"is_preprint":false},{"pmid":"35641352","id":"PMC_35641352","title":"Distal spinal muscular atrophy featured by predominant calf muscle involvement in VRK1 associated disease - Case series and review.","date":"2022","source":"Neuromuscular disorders : NMD","url":"https://pubmed.ncbi.nlm.nih.gov/35641352","citation_count":9,"is_preprint":false},{"pmid":"40990975","id":"PMC_40990975","title":"Histone Lactylation-Driven Upregulation of VRK1 Expression Promotes Stemness and Proliferation of Glioma Stem Cells.","date":"2025","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/40990975","citation_count":7,"is_preprint":false},{"pmid":"34374295","id":"PMC_34374295","title":"VRK1 promotes proliferation, migration, and invasion of gastric carcinoma cells by activating β-catenin.","date":"2021","source":"Neoplasma","url":"https://pubmed.ncbi.nlm.nih.gov/34374295","citation_count":7,"is_preprint":false},{"pmid":"33177193","id":"PMC_33177193","title":"The Vaccinia Virus B12 Pseudokinase Represses Viral Replication via Interaction with the Cellular Kinase VRK1 and Activation of the Antiviral Effector BAF.","date":"2021","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/33177193","citation_count":7,"is_preprint":false},{"pmid":"38806131","id":"PMC_38806131","title":"ALS-associated VRK1 R321C mutation causes proteostatic imbalance and mitochondrial defects in iPSC-derived motor neurons.","date":"2024","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/38806131","citation_count":6,"is_preprint":false},{"pmid":"27319807","id":"PMC_27319807","title":"Expression of vaccinia-related kinase 1 (VRK1) accelerates cell proliferation but overcomes cell adhesion mediated drug resistance (CAM-DR) in multiple myeloma.","date":"2016","source":"Hematology (Amsterdam, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/27319807","citation_count":6,"is_preprint":false},{"pmid":"37429068","id":"PMC_37429068","title":"Behavioral and neurological effects of Vrk1 deficiency in zebrafish.","date":"2023","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/37429068","citation_count":5,"is_preprint":false},{"pmid":"37547297","id":"PMC_37547297","title":"Downregulation of VRK1 Inhibits Progression of Lung Squamous Cell Carcinoma through DNA Damage.","date":"2023","source":"Canadian respiratory journal","url":"https://pubmed.ncbi.nlm.nih.gov/37547297","citation_count":5,"is_preprint":false},{"pmid":"38536553","id":"PMC_38536553","title":"VRK1 promotes DNA-induced type I interferon production.","date":"2024","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/38536553","citation_count":4,"is_preprint":false},{"pmid":"35543552","id":"PMC_35543552","title":"Dysregulation of Cellular VRK1, BAF, and Innate Immune Signaling by the Vaccinia Virus B12 Pseudokinase.","date":"2022","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/35543552","citation_count":4,"is_preprint":false},{"pmid":"38367682","id":"PMC_38367682","title":"Loss of VRK1 alters the nuclear phosphoproteome in the DNA damage response to doxorubicin.","date":"2024","source":"Chemico-biological interactions","url":"https://pubmed.ncbi.nlm.nih.gov/38367682","citation_count":4,"is_preprint":false},{"pmid":"35410639","id":"PMC_35410639","title":"Inhibition of VRK1 suppresses proliferation and migration of vascular smooth muscle cells and intima hyperplasia after injury via mTORC1/β-catenin axis.","date":"2022","source":"BMB reports","url":"https://pubmed.ncbi.nlm.nih.gov/35410639","citation_count":4,"is_preprint":false},{"pmid":"31810390","id":"PMC_31810390","title":"Ras-PI3K pathway promotes osteosarcoma progression via regulating VRK1-mediated H2A phosphorylation at threonine 120.","date":"2019","source":"Artificial cells, nanomedicine, and biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/31810390","citation_count":3,"is_preprint":false},{"pmid":"38732093","id":"PMC_38732093","title":"VRK1 Regulates Sensitivity to Oxidative Stress by Altering Histone Epigenetic Modifications and the Nuclear Phosphoproteome in Tumor Cells.","date":"2024","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38732093","citation_count":3,"is_preprint":false},{"pmid":"38753965","id":"PMC_38753965","title":"Nuclear functions regulated by the VRK1 kinase.","date":"2024","source":"Nucleus (Austin, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/38753965","citation_count":2,"is_preprint":false},{"pmid":"40384864","id":"PMC_40384864","title":"VRK1/BANF1/GLI1 Axis Regulates Tumor Development and Progression of Colorectal Cancer.","date":"2025","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/40384864","citation_count":2,"is_preprint":false},{"pmid":"40234378","id":"PMC_40234378","title":"VRK1 promotes epithelial-mesenchymal transition in hepatocellular carcinoma mediated by SNAI1 via phosphorylating CHD1L.","date":"2025","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/40234378","citation_count":2,"is_preprint":false},{"pmid":"38554151","id":"PMC_38554151","title":"Pathogenic effects of Leu200Pro and Arg387His VRK1 protein variants on phosphorylation targets and H4K16 acetylation in distal hereditary motor neuropathy.","date":"2024","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/38554151","citation_count":2,"is_preprint":false},{"pmid":"40089488","id":"PMC_40089488","title":"Lentinan suppresses the progression of neuroblastoma by inhibiting FOS-mediated transcription activation of VRK1 to stabilize p53 protein.","date":"2025","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/40089488","citation_count":2,"is_preprint":false},{"pmid":"39693713","id":"PMC_39693713","title":"CMT2 and distal hereditary motor neuropathy associated with VRK1 variants: Case series.","date":"2024","source":"Neuromuscular disorders : NMD","url":"https://pubmed.ncbi.nlm.nih.gov/39693713","citation_count":2,"is_preprint":false},{"pmid":"38614421","id":"PMC_38614421","title":"Inactivation of VRK1 sensitizes ovarian cancer to PARP inhibition through regulating DNA-PK stability.","date":"2024","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/38614421","citation_count":1,"is_preprint":false},{"pmid":"36707796","id":"PMC_36707796","title":"Circ VRK1/microRNA-17/PTEN axis modulates the angiogenesis of human brain microvascular endothelial cells to affect injury induced by oxygen-glucose deprivation/reperfusion.","date":"2023","source":"BMC neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/36707796","citation_count":1,"is_preprint":false},{"pmid":"41111449","id":"PMC_41111449","title":"VRK1 Is a Novel Therapeutic Target for Small Cell Neuroendocrine Carcinoma of the Cervix.","date":"2025","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/41111449","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":49809,"output_tokens":10433,"usd":0.152961,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":20740,"output_tokens":7558,"usd":0.146325,"stage2_stop_reason":"end_turn"},"total_usd":0.299286,"stage1_batch_id":"msgbatch_01UT1AahFPCAyn2uVweS7A9z","stage2_batch_id":"msgbatch_01HuKWtKNT4Pqj1bc8eEP5RV","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1997,\n      \"finding\": \"VRK1 was identified as a novel serine/threonine kinase with 40% amino acid identity to vaccinia virus B1R kinase over 305 residues, establishing it as a member of a new kinase family related to, but distinct from, casein kinase 1.\",\n      \"method\": \"cDNA cloning, sequence analysis, Northern blotting\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — sequence-based identification with expression data; foundational structural classification but no in vitro kinase activity demonstrated in this paper\",\n      \"pmids\": [\"9344656\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"VRK1 phosphorylates p53 specifically at threonine-18 (within the mdm-2 binding site/hydrophobic loop), has strong autophosphorylating activity, and phosphorylates acidic substrates (phosvitin, casein) and basic substrates (histone H2B, myelin basic protein). The C-terminal domain (residues 268–396) contains a nuclear localization signal that targets VRK1 to the nucleus.\",\n      \"method\": \"In vitro kinase assay with GST-fusion substrates, autophosphorylation assay, GFP-fusion subcellular localization\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct in vitro kinase assay with defined substrate and site, mutagenesis/domain mapping, GFP localization; replicated by subsequent studies\",\n      \"pmids\": [\"10951572\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"VRK1 phosphorylates ATF2 at Thr-73 and Ser-62, stabilizing ATF2 protein and increasing its intracellular level. VRK1 colocalizes with ATF2 in the nucleus and forms a stable complex. A kinase-dead VRK1 (K179E) or T73A ATF2 substitution prevents ATF2 accumulation and transcriptional activation. VRK1 and JNK have additive effects on ATF2-dependent transcription at suboptimal doses.\",\n      \"method\": \"In vitro kinase assay, co-immunoprecipitation, mutagenesis, transcriptional reporter assay, immunofluorescence colocalization\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assay with site mutagenesis, stable complex by Co-IP, functional transcription assay; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"15105425\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"VRK1 phosphorylates c-Jun at Ser63 and Ser73 in vitro (the same residues targeted by JNK), stabilizes and accumulates c-Jun protein, activates c-Jun-dependent transcription, and interacts with c-Jun but not with JNK. VRK1 and JNK have additive effects on c-Jun transcriptional activation at suboptimal doses.\",\n      \"method\": \"In vitro kinase assay, immunoprecipitation, transcriptional reporter assay, western blot for endogenous phospho-c-Jun\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assay with defined phosphosites, Co-IP, functional transcription assay with site mutants; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"15378002\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"In C. elegans, VRK-1 (the VRK1 ortholog) phosphorylates BAF-1 and regulates BAF localization. VRK-1 localizes to the nuclear envelope and chromatin in a cell-cycle-dependent manner. Depletion of VRK-1 causes mitotic defects including impaired nuclear envelope formation and BAF delocalization.\",\n      \"method\": \"RNAi depletion, temperature-sensitive mutant analysis, live imaging, immunofluorescence in C. elegans embryos\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean RNAi/genetic loss-of-function with specific nuclear envelope phenotype, in vivo localization; replicated in later mammalian studies\",\n      \"pmids\": [\"17170708\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"VRK1 is an early-response gene: its expression is induced upon serum addition to starved cells (paralleling MYC, FOS, CCND1), and its loss via siRNA causes G1 block in cell division with loss of phosphorylated-Rb and cyclin D1.\",\n      \"method\": \"Serum stimulation of starved cells, siRNA knockdown, flow cytometry cell cycle analysis, western blot for proliferation markers\",\n      \"journal\": \"Molecular cancer research : MCR\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA KD with specific cell-cycle phenotype, multiple proliferation markers; single lab\",\n      \"pmids\": [\"16547155\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Most intracellular VRK1 protein is nuclear, but a subpopulation localizes to the cytosol and Golgi apparatus depending on cell type. A T355 phosphomimetic substitution near the nuclear localization signal alters antibody reactivity, suggesting post-translational modification regulates VRK1 subcellular distribution.\",\n      \"method\": \"Immunofluorescence in cell lines, immunohistochemistry of human biopsies, phosphomimetic mutagenesis\",\n      \"journal\": \"Archives of biochemistry and biophysics\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, indirect evidence for regulated localization via antibody reactivity differences; no direct functional consequence demonstrated\",\n      \"pmids\": [\"17617371\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"VRK1 phosphorylates CREB at Ser133 in vitro and in cells. VRK1 facilitates recruitment of phospho-CREB to the CRE element in the CCND1 promoter to drive cyclin D1 expression. Kinase-dead VRK1 or VRK1 siRNA knockdown fails to activate CREB or CRE-driven transcription. VRK1 is a critical link in the CCND1 expression pathway downstream of Myc overexpression.\",\n      \"method\": \"In vitro kinase assay, ChIP, siRNA knockdown, luciferase reporter assay, western blot\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assay, ChIP, kinase-dead mutant, functional reporter; single lab with multiple orthogonal methods\",\n      \"pmids\": [\"18713830\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"VRK1 downregulation by p53 occurs through the autophagic/lysosomal pathway and requires DRAM (a p53-induced gene in the endosomal-lysosomal compartment). DNA damage (UV, IR, etoposide, doxorubicin) stabilizes p53, induces DRAM, and leads to VRK1 downregulation; this process requires nuclear export of VRK1 (blocked by leptomycin B) and Beclin1, and results in reduced p53 Thr18 phosphorylation.\",\n      \"method\": \"siRNA knockdown of DRAM, leptomycin B treatment, LC3/p62 western blot, Beclin1 RNAi, overexpression assays\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple siRNA/OE experiments with mechanistic pathway tracing; single lab\",\n      \"pmids\": [\"21386980\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Plk3 interacts with VRK1, forming a stable complex. Plk3 phosphorylates the C-terminal region of VRK1 at Ser342 but VRK1 does not phosphorylate Plk3. Phosphorylation of VRK1 at Ser342 is required for Golgi fragmentation: VRK1 with S342 substitutions is catalytically active but blocks Golgi fragmentation. VRK1 and Plk3 represent consecutive steps in the MEK1-Plk3-VRK1 Golgi fragmentation cascade.\",\n      \"method\": \"Reciprocal immunoprecipitation, pull-down assay, in vitro kinase assay, siRNA knockdown, immunofluorescence (Golgi marker giantin), dominant-negative approaches\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reciprocal Co-IP, in vitro kinase assay identifying precise phosphosite, site-mutant epistasis with Golgi fragmentation phenotype; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"19103756\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Ran GTPase interacts with and inhibits VRK1 kinase activity. RanGDP (inactive form, especially RanT24N) strongly inhibits VRK1 autophosphorylation and VRK1-mediated histone H3 phosphorylation; active RanGTP or RanL43E relieves this inhibition. Ran does not interact with RCC1 directly through VRK1, but can form a ternary complex. VRK1 does not phosphorylate Ran or RCC1.\",\n      \"method\": \"Pulldown of endogenous proteins, reciprocal immunoprecipitation, mass spectrometry, in vitro kinase assay with Ran mutants\",\n      \"journal\": \"Molecular & cellular proteomics : MCP\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reciprocal Co-IP plus pulldown, in vitro kinase activity assay with defined Ran mutants; single lab with multiple orthogonal methods\",\n      \"pmids\": [\"18617507\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"VRK1 is an early-response gene required for cell cycle entry at G0/G1. siRNA-mediated VRK1 loss results in G1 block, loss of phosphorylated-Rb, cyclin D1, and PCNA, and reduced cell proliferation. VRK1 expression is induced by serum and correlates inversely with p27.\",\n      \"method\": \"siRNA knockdown, serum stimulation, flow cytometry, western blot for cell cycle markers, reporter assay\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA with specific G1 phenotype and multiple proliferation markers; single lab\",\n      \"pmids\": [\"18286197\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"VRK1 hypomorphic mice (GT3/GT3, ~15% wild-type VRK1) are viable but infertile. VRK1 is expressed in Sertoli cells and spermatogonia, and its loss results in a progressive defect in spermatogonial proliferation/differentiation, ultimately eliminating mitotic and meiotic cells from adult testis.\",\n      \"method\": \"Gene-trap mouse genetics, histology, in situ expression analysis\",\n      \"journal\": \"Biology of reproduction\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — hypomorphic mouse genetic analysis with specific spermatogenesis phenotype; single lab\",\n      \"pmids\": [\"19696012\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"In C. elegans, VRK-1 is required for normal germ cell proliferation, and acts in part by negatively regulating CEP-1 (p53) activity. Loss of cep-1 significantly rescues vrk-1 proliferation defects, placing VRK-1 upstream of CEP-1/p53 in germline proliferation control.\",\n      \"method\": \"Genome-wide RNAi screen, genetic epistasis (double mutant rescue), gene expression profiling\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis by double mutant rescue; single lab\",\n      \"pmids\": [\"20599896\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"NMR solution structure of catalytically active human VRK1 (residues 1–361) revealed that the C-terminal tail orients toward the catalytic site and forms interactions critical for structural stability and catalysis. Deletion of the C-terminal tail dramatically reduces autocatalytic activity. ATP binding involves the hinge region, catalytic loop, and DYG motif, with additional contacts from C-terminal tail residues.\",\n      \"method\": \"NMR solution structure determination, deletion mutant kinase assays, NMR titration with ATP/ATP analogs\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — NMR structure combined with deletion mutagenesis and kinase activity assays; multiple orthogonal methods in single study\",\n      \"pmids\": [\"21543316\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"MacroH2A1.2 directly interacts with VRK1 and suppresses VRK1-mediated histone H3 phosphorylation during interphase. MacroH2A1.2 levels are markedly reduced in mitosis, thereby relieving VRK1 inhibition. VRK1-macroH2A1.2 interaction was confirmed by NMR spectroscopy.\",\n      \"method\": \"Co-immunoprecipitation, NMR spectroscopy (binding characterization), cell cycle synchronization, western blot for H3 phosphorylation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct binding confirmed by NMR, in-cell functional data with cell cycle correlation; single lab, two orthogonal methods\",\n      \"pmids\": [\"22194607\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"The kinase VRK1 is required for normal meiotic progression in female mouse oogenesis. VRK1 reduction (gene-trap hypomorph) causes delayed meiotic progression, lagging chromosomes at the metaphase plate, and failure of oocyte fertilization. These defects are independent of p53 activity.\",\n      \"method\": \"Gene-trap mouse hypomorph, histology, meiotic chromosome spreads, p53 knockout epistasis\",\n      \"journal\": \"Mechanisms of development\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic loss-of-function with specific meiotic phenotype and epistasis test; single lab\",\n      \"pmids\": [\"21277975\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"VRK1 directly phosphorylates 53BP1 in serum-starved cells in response to ionizing radiation-induced double-strand breaks. VRK1 knockdown causes defective 53BP1 foci formation (reduced number and size) after IR; this effect is p53- and ATM-independent and is rescued by siRNA-resistant VRK1 mutants. VRK1 knockdown also prevents activating phosphorylation of ATM, CHK2, and DNA-PK in response to IR.\",\n      \"method\": \"In vitro kinase assay, siRNA knockdown, immunofluorescence for 53BP1 foci, western blot for ATM/CHK2/DNA-PK phosphorylation, siRNA-resistant rescue constructs\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assay, siRNA KD with specific foci phenotype, siRNA-resistant rescue, ATM-independent epistasis; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"22621922\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"VRK1 phosphorylates hnRNP A1, and this phosphorylation potentiates hnRNP A1 binding to telomeric ssDNA and telomerase RNA in vitro, and enhances telomerase activity. VRK1 deficiency in mouse male germ cells causes telomere shortening with abnormal telomere arrangement and activation of DNA-damage signaling.\",\n      \"method\": \"In vitro kinase assay, EMSA (ssDNA binding), telomerase activity assay, mouse VRK1 hypomorph analysis\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assay plus functional binding and telomerase assays; single lab, in vivo corroboration from mouse model\",\n      \"pmids\": [\"22740652\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"VRK1 depletion in MCF10a and MDA-MB-231 cells causes aberrant nuclear envelope architecture. GFP-BAF FRAP analysis shows elevated immobile fraction at the nuclear envelope in VRK1-depleted cells, indicating prolonged BAF-partner interactions. In VRK1-depleted cells, BAF does not disperse at mitosis onset but remains chromosome-bound throughout mitosis. VRK1 depletion also increases anaphase bridges and multipolar spindles.\",\n      \"method\": \"siRNA knockdown, FRAP of GFP-BAF, live-cell imaging, immunofluorescence for mitotic phenotypes\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean KD with live-cell FRAP and imaging demonstrating specific BAF dynamics phenotype; independently consistent with C. elegans findings\",\n      \"pmids\": [\"24430874\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"VRK1 forms a basal stable complex with p53 through the p53 DNA-binding domain. UV-induced DNA damage activates VRK1 and triggers phosphorylation of p53 at Thr-18 before p53 accumulates. Frequent DNA-contact p53 mutants (R273H, R248H, R280K) do not disrupt the VRK1-p53 complex.\",\n      \"method\": \"Co-immunoprecipitation, in vitro kinase assay, UV treatment, western blot for phospho-p53 Thr18\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP demonstrating stable complex, in vitro kinase assay, single lab\",\n      \"pmids\": [\"24492002\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"VRK1 is a nucleosomal chromatin kinase that directly and stably interacts with histones H2AX and H3. VRK1 depletion causes loss of H3 and H4 acetylation (required for chromatin relaxation) in basal conditions and after DNA damage, independently of ATM. In response to ionizing radiation, VRK1 phosphorylates histone H2AX at Ser139 (γH2AX); VRK1 depletion prevents γH2AX foci formation, which is rescued by kinase-active but not kinase-dead VRK1.\",\n      \"method\": \"Chromatin fractionation, Co-immunoprecipitation with histones, siRNA knockdown, ionizing radiation, immunofluorescence for γH2AX foci, kinase-dead rescue\",\n      \"journal\": \"Epigenetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — chromatin fractionation, Co-IP with histones, in-cell kinase assay with kinase-dead rescue; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"25923214\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"VRK1 directly interacts with and phosphorylates coilin at Ser184. Phosphorylation of coilin by VRK1 occurs during mitosis and regulates coilin stability: VRK1 knockdown or inactivation causes loss of coilin phosphorylation and Cajal body (CB) disassembly, leading to coilin ubiquitination (partly mediated by mdm2) and proteasomal degradation in the cytosol (after nuclear export). Kinase-active but not kinase-dead VRK1 rescues CB formation.\",\n      \"method\": \"Co-immunoprecipitation, in vitro kinase assay, siRNA knockdown, immunofluorescence, proteasome inhibitor (MG132), nuclear export inhibitor\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assay identifying phosphosite, Co-IP, kinase-dead rescue, proteasome/export inhibitor mechanistic dissection; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"26068304\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"VRK1 regulates neuronal migration and neuronal stem cell proliferation. In utero electroporation shRNA knockdown of Vrk1 in mice impairs cortical neuronal migration and affects cell cycle of neuronal progenitors; wild-type human VRK1 rescues both phenotypes. Kinase-dead VRK1 rescues migration but not proliferation, indicating the migration role is partly non-catalytic. VRK1 deficiency reduces amyloid-β precursor protein (APP) levels, and APP overexpression rescues the Vrk1 knockdown neuronal migration phenotype.\",\n      \"method\": \"In utero electroporation shRNA, cortical migration assay, kinase-dead rescue, western blot for APP, APP overexpression rescue\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo shRNA with specific neuronal migration phenotype, kinase-dead vs. WT rescue, epistasis through APP; single lab\",\n      \"pmids\": [\"25609612\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"VRK1 phosphorylates NBS1 at Ser343, forming a basal preassembled complex with NBS1 in non-damaged cells. VRK1 knockdown causes loss of NBS1 foci after ionizing radiation (also in cell-cycle arrested and ATM−/− cells). NBS1 phosphorylation by VRK1 (induced by doxorubicin or IR) contributes to NBS1 stability: loss of this phosphorylation can be prevented by MG132 proteasome inhibitor or RNF8 knockdown.\",\n      \"method\": \"Co-immunoprecipitation, in vitro kinase assay (ATM−/− cells), siRNA knockdown, immunofluorescence for NBS1 foci, proteasome inhibitor treatment\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — basal complex by Co-IP, in vitro kinase assay defining phosphosite, ATM-independent genetic context, proteasome mechanistic link; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"26869104\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"VRK1 phosphorylates pregnane X receptor (PXR) at Ser350 in response to low glucose conditions, enabling PXR to scaffold PP2Cα, which dephosphorylates SGK2 at Thr193, releasing SGK2 repression of the PCK1 gluconeogenesis gene. CDK2 inhibits VRK1 activity toward PXR under high glucose conditions, forming a VRK1-CDK2-PXR-PP2Cα-SGK2 pathway regulating gluconeogenesis.\",\n      \"method\": \"In vitro kinase assay, co-immunoprecipitation, cell-based phosphorylation assays, CDK2 inhibition, fasting mouse liver analysis\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assay with defined phosphosite, co-IP, in vivo fasting mouse corroboration; single lab\",\n      \"pmids\": [\"28911860\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"VRK1 and Aurora B (AURKB) form a stable protein complex (minor subpopulation, detected after nocodazole release). Each kinase inhibits the kinase activity of the other, and each inhibits the other's phosphorylation of histone H3 (VRK1 on Thr3, AURKB on Ser10). VRK1 depletion downregulates BIRC5 (survivin) expression and is rescued by kinase-active but not kinase-dead VRK1; loss of the H3-Thr3ph–survivin complex prevents AURKB localization to centromeres.\",\n      \"method\": \"Co-immunoprecipitation, in vitro kinase assay (cross-inhibition), siRNA knockdown, immunofluorescence, kinase-active vs. kinase-dead rescue\",\n      \"journal\": \"Cellular and molecular life sciences : CMLS\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — Co-IP, in vitro mutual inhibition assay, specific mitotic phenotypes with rescue; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"29340707\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"In C. elegans, VRK-1 directly phosphorylates and activates AMPK, promoting longevity. VRK-1 overexpression increases lifespan and inhibition decreases lifespan; vrk-1 is required for longevity conferred by inhibited mitochondrial respiration (which requires AMPK). VRK-1 directly phosphorylates and upregulates AMPK in both C. elegans and human cultured cells.\",\n      \"method\": \"In vitro kinase assay (direct phosphorylation of AMPK), C. elegans lifespan assays, genetic epistasis with AMPK mutants, overexpression in cultured human cells\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro direct kinase assay, genetic epistasis in C. elegans, conserved in human cells; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"32937443\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"VRK1 directly phosphorylates Tip60/KAT5 in the chromatin fraction in response to DNA damage (doxorubicin). VRK1 depletion causes loss of Tip60 phosphorylation in both ATM+/+ and ATM−/− cells; kinase-active but not kinase-dead VRK1 rescues Tip60 phosphorylation. VRK1-mediated Tip60 phosphorylation is necessary for Tip60 acetyltransferase activity toward ATM (activating acetylation) and subsequent ATM autophosphorylation; both are lost by VRK1 depletion.\",\n      \"method\": \"In vitro kinase assay, Co-immunoprecipitation, siRNA knockdown (ATM+/+ and ATM−/− cells), Tip60 inhibitor (MG149), kinase-active/dead rescue\",\n      \"journal\": \"Cancers\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assay, ATM-independent genetic context, kinase-dead rescue; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"33076429\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Vaccinia virus B12 pseudokinase directly interacts with VRK1 (as the most enriched B12 interactor by proteomics), and B12 interferes with VRK1's ability to phospho-inactivate BAF. VRK1 is required for rescue of B1-deleted virus; VRK1 overexpression overcomes B12-mediated repression of viral replication. B12 promotes VRK1 colocalization with cellular DNA during mitosis.\",\n      \"method\": \"Protein interactome (mass spectrometry), VRK1 knockdown and overexpression assays, viral replication assays, immunofluorescence\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — MS interactome plus functional VRK1 KD/OE in viral context; single lab\",\n      \"pmids\": [\"33177193\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"VRK1 interacts with both linker DNA and the nucleosome acidic patch to phosphorylate histone H3T3. Acidic patch binding is mediated by a C-terminal arginine-rich flexible tail. Disease-associated missense and nonsense mutations in this C-terminal acidic patch recognition motif disrupt nucleosome acidic patch binding and cause VRK1 mislocalization during mitosis.\",\n      \"method\": \"Cryo-electron microscopy, biochemical binding assays (chromatin/nucleosome), cellular localization assays (mitosis), analysis of disease-associated mutants\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — cryo-EM structure with biochemical validation, disease-mutant functional testing, cellular localization consequence; single study with multiple orthogonal methods\",\n      \"pmids\": [\"35390161\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"VRK1 and VRK2 are synthetic-lethal paralogs. In VRK2-null/methylated glioblastoma cells, VRK1 knockdown reduces phosphorylation of BAF, causing nuclear lobulation, blebbing, and micronucleation, followed by G2-M arrest and DNA damage. The synthetic-lethal interaction requires VRK1 kinase activity and is rescued by ectopic VRK2 expression.\",\n      \"method\": \"CRISPR/Cas9 knockdown, VRK2 ectopic expression rescue, phospho-BAF western blot, live-cell imaging (nuclear morphology), flow cytometry (G2-M arrest), xenograft models\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic tools (KD, rescue), specific downstream substrate (BAF), cellular and in vivo phenotypes; replicated in independent study (So et al., 2022)\",\n      \"pmids\": [\"36069976\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"The VRK1 chromatin kinase regulates Tip60/KAT5 through sequential phosphorylation events: VRK1 phosphorylates Tip60 at T158 (early, transient), which protects Tip60 from ubiquitin-mediated degradation, promotes its recruitment from nucleoplasm to chromatin, and is necessary for full trans-acetylase activity. DNA-PK subsequently phosphorylates Tip60 at S199, enabling Tip60 autoacetylation; however, full trans-acetylation of H4 and ATM requires both T158 and S199 phosphorylation.\",\n      \"method\": \"In vitro kinase assay, phosphomimetic and phosphonull mutants, Co-immunoprecipitation, chromatin fractionation, DNA-PK inhibitor treatment\",\n      \"journal\": \"Biochimica et biophysica acta. Gene regulatory mechanisms\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assay identifying phosphosites, phosphomutant functional assays, chromatin fractionation; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"36280132\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Using in vitro kinase assays, KiPIK screening, RNAi, and CRISPR/Cas9 approaches, VRK1 and its paralog VRK2 could NOT be substantiated as the kinases responsible for histone H3 Thr3 or Ser10 phosphorylation during mitosis; Haspin is the kinase responsible for H3T3ph in mitosis. Loss of VRK1 did slow cell proliferation.\",\n      \"method\": \"In vitro kinase assays, KiPIK screening, RNA interference, CRISPR/Cas9 knockout\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — multiple rigorous approaches (in vitro assay, KiPIK, RNAi, CRISPR) converging on a negative result; single lab but orthogonal methods\",\n      \"pmids\": [\"35778595\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"In zebrafish, Ankle2 deficiency causes microcephaly and spermatogenesis defects through dysregulated BAF phosphorylation. Heterozygous deletion of vrk1 or vrk1 morpholino knockdown rescues the Ankle2-deficient microcephaly and partially rescues spermatogenesis defects, placing VRK1 downstream of ANKLE2 in the BAF phosphorylation pathway regulating neurogenesis.\",\n      \"method\": \"Zebrafish genetic knockout and morpholino knockdown, genetic epistasis, brain size measurement, cell proliferation assays\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis with specific rescue of neurogenesis phenotype; single lab\",\n      \"pmids\": [\"35940133\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"VRK1 kinase activity is inhibited by direct interaction with SIRT2 deacetylase through VRK1's N-terminal kinase domain. VRK1-SIRT2 interaction causes loss of H4K16 acetylation (similar to VRK1 inhibitor VRK-IN-1 or VRK1 depletion). SIRT2 inhibitors increase H4K16ac, cooperating with VRK1 in chromatin accessibility in response to DNA damage.\",\n      \"method\": \"In vitro interaction/pull-down assay, in vitro kinase assay, Co-immunoprecipitation, immunofluorescence, H4K16ac western blot\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro pull-down and kinase inhibition, Co-IP, functional acetylation readout; single lab\",\n      \"pmids\": [\"36902348\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"VRK1 promotes DNA-induced type I interferon production through the cGAS-STING pathway. VRK1 knockdown attenuates induction of type I IFNs and ISGs following HTDNA and Poly(dA:dT) stimulation; VRK-IN-1 (VRK1 inhibitor) similarly suppresses IFN-I induction. VRK1 potentiates the cGAS-STING-IFN-I axis at the level of STING.\",\n      \"method\": \"siRNA knockdown, pharmacological inhibition (VRK-IN-1), real-time PCR, dual-luciferase reporter assay in human and murine cell lines and primary BMDMs\",\n      \"journal\": \"Molecular biology reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA KD and pharmacological inhibition with consistent IFN reporter results; single lab, mechanism placement at STING level\",\n      \"pmids\": [\"38536553\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"VRK1 directly interacts with and phosphorylates CHD1L at serine 122. VRK1-CHD1L-SNAI1 forms an axis by which VRK1 promotes EMT in hepatocellular carcinoma: VRK1 phosphorylation of CHD1L upregulates SNAI1 expression (identified by RNA-seq as a key downstream target).\",\n      \"method\": \"Immunoprecipitation combined with mass spectrometry, in vitro kinase assay (phosphosite identification), RNA-seq, VRK1 overexpression/knockdown functional assays\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — Co-IP/MS, in vitro kinase assay with phosphosite, RNA-seq pathway analysis; single lab\",\n      \"pmids\": [\"40234378\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"VRK1 is a nuclear serine/threonine chromatin kinase that phosphorylates multiple substrates—including p53 (Thr18), ATF2 (Thr73/Ser62), c-Jun (Ser63/Ser73), CREB (Ser133), histone H2AX (Ser139), histone H3 (Thr3 in interphase contexts), BAF/BANF1, 53BP1, NBS1 (Ser343), coilin (Ser184), hnRNP A1, Tip60/KAT5 (T158), AMPK, PXR (Ser350), and CHD1L (Ser122)—to regulate cell cycle entry (G0/G1 transition and cyclin D1 expression), nuclear envelope assembly/disassembly via BAF dynamics, Cajal body assembly via coilin stability, chromatin relaxation and histone acetylation (H4K16ac via Tip60 activation), DNA damage responses (γH2AX, NBS1, and 53BP1 foci formation independent of ATM), Golgi fragmentation (as a Plk3-phosphorylated downstream effector at Ser342), and nucleosome engagement through an acidic-patch-binding C-terminal arginine-rich tail; its kinase activity is negatively regulated by RanGDP and macroH2A1.2, and by cross-inhibition with Aurora B, while a paralog synthetic-lethal relationship with VRK2 means VRK2-deficient cancers are uniquely dependent on VRK1.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"VRK1 is a nuclear serine/threonine chromatin kinase that couples mitogenic and genotoxic signals to cell cycle entry, chromatin dynamics, nuclear envelope organization, and DNA damage responses [#1, #11, #21]. It was originally cloned as a kinase distantly related to vaccinia virus B1R [#0] and shown to autophosphorylate and phosphorylate p53 at Thr18 within the MDM2-binding loop, with a C-terminal nuclear localization signal directing it to the nucleus [#1]. As an early-response gene induced by serum, VRK1 drives the G0/G1 transition: its loss blocks cells in G1 with reduced phospho-Rb, cyclin D1, and PCNA [#5, #11], and it activates cyclin D1 expression by phosphorylating CREB at Ser133 and promoting its recruitment to the CCND1 promoter [#7]. VRK1 stabilizes and activates the transcription factors ATF2 and c-Jun through phosphorylation, paralleling JNK targeting [#2, #3]. In the DNA damage response, VRK1 acts upstream of and independently of ATM, phosphorylating histone H2AX (Ser139/\\u03b3H2AX), NBS1 (Ser343), and 53BP1 to support damage focus formation, and phosphorylating Tip60/KAT5 at T158 to license its acetyltransferase activity toward histones and ATM [#17, #21, #24, #28, #32]. Structural work defined a C-terminal tail that folds onto the catalytic site and an arginine-rich tail that engages linker DNA and the nucleosome acidic patch for histone H3T3 phosphorylation; disease-associated mutations in this motif disrupt nucleosome binding and mitotic localization [#14, #30]. VRK1 regulates nuclear envelope assembly and mitotic chromosome segregation by phosphorylating BAF/BANF1, controlling its dynamic dissociation from chromatin [#4, #19], and maintains Cajal bodies by phosphorylating coilin at Ser184 to prevent its degradation [#22]. Its kinase activity is negatively regulated by RanGDP, macroH2A1.2, SIRT2, and reciprocal cross-inhibition with Aurora B [#10, #15, #26, #35]. VRK1 and its paralog VRK2 are synthetic-lethal, rendering VRK2-deficient cancers selectively dependent on VRK1 via BAF phosphorylation [#31]. Beyond its core nuclear roles, VRK1 also acts in a Plk3-driven Golgi fragmentation cascade [#9], gluconeogenic signaling via PXR [#25], AMPK activation and longevity [#27], cGAS-STING interferon signaling [#36], and EMT through a CHD1L-SNAI1 axis [#37].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Established VRK1 as a distinct serine/threonine kinase family member, providing the molecular identity needed to study its function.\",\n      \"evidence\": \"cDNA cloning and sequence analysis against vaccinia B1R kinase\",\n      \"pmids\": [\"9344656\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No in vitro kinase activity or substrate demonstrated\", \"No subcellular localization or cellular role defined\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Demonstrated VRK1 is a catalytically active nuclear kinase with p53 Thr18 as a defined substrate, opening the link to the p53 stress-response axis.\",\n      \"evidence\": \"In vitro kinase assays with GST substrates, autophosphorylation, GFP localization and domain mapping\",\n      \"pmids\": [\"10951572\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of p53 Thr18 phosphorylation not resolved in cells\", \"Physiological substrate repertoire still unknown\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Extended VRK1 substrate scope to AP-1 transcription factors, showing it stabilizes and activates ATF2 and c-Jun in parallel with the JNK pathway.\",\n      \"evidence\": \"In vitro kinase assays, Co-IP, site mutagenesis, and transcriptional reporters\",\n      \"pmids\": [\"15105425\", \"15378002\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo physiological context of these phosphorylations unclear\", \"Relative contribution versus JNK not quantified\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Defined VRK1 as a serum-induced early-response gene required for the G0/G1 transition, framing it as a proliferation driver.\",\n      \"evidence\": \"Serum stimulation, siRNA knockdown, flow cytometry, cell-cycle marker western blots\",\n      \"pmids\": [\"16547155\", \"18286197\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct kinase substrates mediating G1 arrest not identified here\", \"Single-lab phenotype\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Established the conserved nuclear-envelope role of VRK1 via BAF phosphorylation using a genetically tractable in vivo model.\",\n      \"evidence\": \"RNAi and temperature-sensitive mutants with live imaging in C. elegans\",\n      \"pmids\": [\"17170708\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct BAF phosphosite not defined in this study\", \"Mammalian conservation not yet shown at this stage\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Mechanistically connected VRK1 to cyclin D1 induction through CREB Ser133 phosphorylation and promoter recruitment, downstream of Myc.\",\n      \"evidence\": \"In vitro kinase assay, ChIP, kinase-dead mutant, luciferase reporter\",\n      \"pmids\": [\"18713830\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How serum/Myc signal activates VRK1 not resolved\", \"Endogenous CREB occupancy dynamics not fully mapped\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identified upstream regulatory inputs: Plk3 phosphorylates VRK1 at Ser342 to drive Golgi fragmentation, and RanGDP inhibits VRK1 activity, revealing signal-dependent control.\",\n      \"evidence\": \"Reciprocal Co-IP, in vitro kinase assays, site-mutant epistasis, pulldown with Ran mutants\",\n      \"pmids\": [\"19103756\", \"18617507\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological trigger linking Ran nucleotide state to VRK1 in vivo unclear\", \"Golgi role mechanism downstream of Ser342 incomplete\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Showed a feedback loop in which p53 downregulates VRK1 via DRAM-dependent autophagy, defining reciprocal regulation between VRK1 and p53.\",\n      \"evidence\": \"DRAM/Beclin1 siRNA, leptomycin B, autophagy marker western blots\",\n      \"pmids\": [\"21386980\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct mechanism of VRK1 autophagic targeting not defined\", \"Single-lab pathway tracing\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Demonstrated physiological requirement for VRK1 in proliferating germline tissue through a hypomorphic mouse with spermatogenesis failure.\",\n      \"evidence\": \"Gene-trap mouse genetics, histology, expression analysis\",\n      \"pmids\": [\"19696012\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular substrate underlying spermatogonial defect not identified here\", \"Hypomorph rather than null\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Placed VRK1 genetically upstream of p53 in controlling germ cell proliferation, reinforcing a conserved VRK1\\u2013p53 antagonism.\",\n      \"evidence\": \"Genome-wide RNAi and double-mutant epistasis in C. elegans\",\n      \"pmids\": [\"20599896\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct biochemical link to CEP-1/p53 not established\", \"Mechanism of negative regulation unclear\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Provided the structural basis of VRK1 catalysis, showing the C-terminal tail is integral to activity, and identified macroH2A1.2 as a cell-cycle-dependent inhibitor.\",\n      \"evidence\": \"NMR solution structure, deletion-mutant kinase assays, NMR binding of macroH2A1.2\",\n      \"pmids\": [\"21543316\", \"22194607\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full-length structure including arginine-rich tail not resolved here\", \"How macroH2A1.2 occludes catalysis structurally unknown\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Extended VRK1's developmental requirement to female meiosis, with chromosome segregation defects independent of p53.\",\n      \"evidence\": \"Gene-trap hypomorph, meiotic chromosome spreads, p53-knockout epistasis\",\n      \"pmids\": [\"21277975\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Substrate driving meiotic defect not identified\", \"Hypomorphic rather than null\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Established VRK1 as an ATM-independent apical DNA damage response kinase that phosphorylates 53BP1 and supports damage signaling and telomere maintenance via hnRNP A1.\",\n      \"evidence\": \"In vitro kinase assays, siRNA with focus quantification, siRNA-resistant rescue, EMSA and telomerase assays\",\n      \"pmids\": [\"22621922\", \"22740652\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How VRK1 is activated by double-strand breaks unresolved\", \"Direct 53BP1 phosphosite not defined\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Quantified VRK1's control of BAF mobility in mammalian cells, linking BAF phosphorylation to nuclear envelope architecture and faithful mitosis.\",\n      \"evidence\": \"siRNA knockdown, GFP-BAF FRAP, live-cell imaging, mitotic phenotype scoring\",\n      \"pmids\": [\"24430874\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct BAF phosphosite in mammalian cells not mapped here\", \"Spatial coordination of BAF phosphorylation cycle incomplete\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Showed VRK1 forms a basal complex with p53 via its DNA-binding domain and rapidly phosphorylates Thr18 upon UV damage before p53 accumulation.\",\n      \"evidence\": \"Co-IP, in vitro kinase assay, UV treatment, phospho-p53 western blot\",\n      \"pmids\": [\"24492002\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Stoichiometry and dynamics of the preassembled complex unclear\", \"Reciprocal validation limited\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Defined VRK1 as a nucleosomal chromatin kinase required for histone acetylation and \\u03b3H2AX formation, and as a regulator of Cajal body integrity and neuronal development.\",\n      \"evidence\": \"Chromatin fractionation, histone Co-IP, kinase-dead rescue, coilin phosphosite mapping, in utero electroporation shRNA\",\n      \"pmids\": [\"25923214\", \"26068304\", \"25609612\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism linking VRK1 to H3/H4 acetylation machinery only partly defined\", \"Non-catalytic migration function mechanism unknown\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Identified NBS1 Ser343 as a VRK1 substrate within a preassembled complex, contributing to NBS1 stability and ATM-independent damage focus formation.\",\n      \"evidence\": \"Co-IP, in vitro kinase assay in ATM-/- cells, focus imaging, proteasome inhibition, RNF8 knockdown\",\n      \"pmids\": [\"26869104\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Integration with canonical MRN/ATM signaling not fully resolved\", \"Single-lab\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Expanded VRK1 into metabolic signaling, phosphorylating PXR Ser350 to control a gluconeogenic cascade gated by CDK2 and glucose status.\",\n      \"evidence\": \"In vitro kinase assay, Co-IP, glucose-dependent assays, fasting mouse liver\",\n      \"pmids\": [\"28911860\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Tissue-specificity and physiological magnitude unclear\", \"Single-lab pathway\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Revealed mutual cross-inhibition between VRK1 and Aurora B over histone H3 phosphorylation, coupling VRK1 to mitotic survivin/centromere function.\",\n      \"evidence\": \"Co-IP, in vitro cross-inhibition kinase assays, kinase-active vs dead rescue, mitotic imaging\",\n      \"pmids\": [\"29340707\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Spatiotemporal regulation of the antagonism in mitosis unclear\", \"Structural basis of cross-inhibition unknown\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Mechanistically dissected VRK1 control of Tip60/KAT5, showing T158 phosphorylation licenses Tip60 acetyltransferase activity toward ATM and histones in a sequential code with DNA-PK.\",\n      \"evidence\": \"In vitro kinase assays, ATM-/- context, phosphomutants, chromatin fractionation, DNA-PK inhibition\",\n      \"pmids\": [\"33076429\", \"36280132\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Ordering of VRK1 versus DNA-PK inputs across damage types incomplete\", \"Single-lab\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Demonstrated a conserved VRK1 role in activating AMPK to promote longevity, broadening its substrate range beyond chromatin.\",\n      \"evidence\": \"In vitro kinase assay, C. elegans lifespan and epistasis, human cell corroboration\",\n      \"pmids\": [\"32937443\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"AMPK phosphosite and mammalian physiological role not defined\", \"Link to nuclear functions unclear\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Showed vaccinia B12 pseudokinase targets VRK1 to block its inactivation of BAF, defining a host-pathogen control point at the VRK1\\u2013BAF interface.\",\n      \"evidence\": \"Proteomic interactome, VRK1 KD/OE, viral replication assays, imaging\",\n      \"pmids\": [\"33177193\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct biochemical mechanism of B12 inhibition unresolved\", \"Single-lab\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Provided the structural mechanism of nucleosome engagement, showing an arginine-rich C-terminal tail binds the acidic patch and linker DNA, with disease mutations disrupting this and mitotic localization.\",\n      \"evidence\": \"Cryo-EM, nucleosome binding assays, disease-mutant localization tests\",\n      \"pmids\": [\"35390161\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of disrupted acidic-patch binding on substrate phosphorylation in vivo incomplete\", \"Disease genotype-phenotype not mapped here\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Established VRK1\\u2013VRK2 synthetic lethality through BAF phosphorylation, defining a therapeutic dependency in VRK2-deficient cancers.\",\n      \"evidence\": \"CRISPR knockdown, VRK2 rescue, phospho-BAF blots, imaging, flow cytometry, xenografts\",\n      \"pmids\": [\"36069976\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Determinants of selectivity beyond BAF unclear\", \"Resistance mechanisms not addressed\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Challenged the assignment of mitotic H3T3/S10 phosphorylation to VRK1, attributing mitotic H3T3ph to Haspin and constraining VRK1's interphase chromatin role.\",\n      \"evidence\": \"In vitro kinase assays, KiPIK screening, RNAi, CRISPR knockout\",\n      \"pmids\": [\"35778595\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Reconciliation with VRK1 H3T3 activity reported elsewhere unresolved\", \"Context-dependence of H3 phosphorylation not settled\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identified SIRT2 as a direct inhibitor of VRK1 controlling H4K16 acetylation and chromatin accessibility during the damage response.\",\n      \"evidence\": \"In vitro pull-down and kinase inhibition, Co-IP, H4K16ac western blot, imaging\",\n      \"pmids\": [\"36902348\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether inhibition is allosteric or steric unclear\", \"Single-lab\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Linked VRK1 to innate immune signaling, showing it potentiates cGAS-STING-dependent type I interferon production at the STING level.\",\n      \"evidence\": \"siRNA, VRK-IN-1 inhibition, qPCR and reporter assays in human/murine cells and BMDMs\",\n      \"pmids\": [\"38536553\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct STING-pathway substrate not identified\", \"Mechanism of STING-level potentiation unresolved\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Defined a VRK1\\u2013CHD1L\\u2013SNAI1 axis driving EMT in hepatocellular carcinoma, extending VRK1's oncogenic reach.\",\n      \"evidence\": \"Co-IP/MS, in vitro kinase assay with phosphosite, RNA-seq, KD/OE functional assays\",\n      \"pmids\": [\"40234378\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo tumor relevance not fully established\", \"Single-lab\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How VRK1 kinase activity is switched on by distinct mitogenic versus genotoxic upstream signals, and how its many substrate engagements are spatially and temporally prioritized, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model of VRK1 activation upstream of DNA damage\", \"Substrate selection logic across cell-cycle phases undefined\", \"Context dependence of H3T3 phosphorylation unsettled\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [1, 2, 3, 7, 17, 21, 22, 24, 28, 30, 32, 37]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 1, 14]},\n      {\"term_id\": \"GO:0042393\", \"supporting_discovery_ids\": [21, 30]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [30]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [26, 28, 32, 35]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [1, 6, 21]},\n      {\"term_id\": \"GO:0000228\", \"supporting_discovery_ids\": [4, 21, 30]},\n      {\"term_id\": \"GO:0005635\", \"supporting_discovery_ids\": [4, 19]},\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [6, 9]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [6]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [5, 7, 11, 19, 26]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [17, 21, 24, 28, 32]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [21, 28, 30, 32, 35]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [2, 3, 7, 37]},\n      {\"term_id\": \"R-HSA-1852241\", \"supporting_discovery_ids\": [4, 19, 22]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"TP53\", \"ATF2\", \"JUN\", \"BANF1\", \"NBS1\", \"KAT5\", \"AURKB\", \"PLK3\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":10,"faith_total":10,"faith_pct":100.0}}